Innoviva Inc
Buy, Hold or Sell?

Let's analyse Innoviva Inc together

Penke I guess you are interested in Innoviva Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Innoviva Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Innoviva Inc

I send you an email if I find something interesting about Innoviva Inc.

Quick analysis of Innoviva Inc (30 sec.)

What can you expect buying and holding a share of Innoviva Inc? (30 sec.)

How much money do you get?

$0.00

When do you have the money?

1 year

How often do you get paid?

57.5%

What is your share worth?

Current worth

$7.94

Expected worth in 1 year

$7.76

How sure are you?

70.0%

+ What do you gain per year?

Total Gains per Share

$-0.18

Return On Investment

-1.2%

For what price can you sell your share?

Current Price per Share

$15.17

Expected price per share

$14.08 - $15.39

How sure are you?

50%

1. Valuation of Innoviva Inc (5 min.)

Live pricePrice per Share (EOD)

$15.17

Book Value per Share

$7.94

Intrinsic Value Per Share

$-6.23 - $41.66

Total Value Per Share

$1.71 - $49.60

My calculation of the intrinsic value of Innoviva Inc is based how much money is coming from the company's main activities (Free Cash Flow).

The following numbers are based on moving averages and per share and per quarter.
I use a 6% discount rate for the low estimation and 3% for the high estimation.
The current Free Cash Flow Per Share is 10Y: ($0.35) 3Y: ($0.64) TTM: ($0.44)
The change per quarter (trend) of the Free Cash Flow Per Share is 10Y: ($0.03) 3Y: ($-0.03) TTM: ($0.07)

Years	Total Low est.	Total High est.	Added Free Cash Flow
1	$1.07	$2.78	$0.93 - $3.01
2	$1.64	$5.93	$0.45 - $3.48
3	$1.77	$9.42	$-0.04 - $3.95
4	$1.50	$13.23	$-0.52 - $4.42
5	$0.87	$17.34	$-1.00 - $4.89
6	$-0.06	$21.72	$-1.48 - $5.36
7	$-1.28	$26.37	$-1.96 - $5.83
8	$-2.73	$31.25	$-2.45 - $6.29
9	$-4.39	$36.35	$-2.93 - $6.76
10	$-6.23	$41.66	$-3.41 - $7.23

2. Growth of Innoviva Inc (5 min.)

Is Innoviva Inc growing?

	Current year	Previous year	Grow	Grow %
How rich?	$674.9m	$581.2m	$23.5m	3.9%

How much money is Innoviva Inc making?

	Current year	Previous year	Grow	Grow %
Making money	$44.9m	$53.4m	-$8.5m	-19.0%
Net Profit Margin	59.5%	77.3%	-	-

How much money comes from the company's main activities?

Quarterly Yearly

3. Financial Health of Innoviva Inc (5 min.)

4. Comparing to competitors in the Biotechnology industry (5 min.)

Industry Rankings (Biotechnology)

Richest
#80 / 1009

Most Revenue
#113 / 1009

Most Profit
#52 / 1009

Most Efficient
#29 / 1009

What can you expect buying and holding a share of Innoviva Inc? (5 min.)

Welcome investor! Innoviva Inc's management wants to use your money to grow the business. In return you get a share of Innoviva Inc.

What can you expect buying and holding a share of Innoviva Inc?

First you should know what it really means to hold a share of Innoviva Inc. And how you can make/lose money.

Speculation

The Price per Share of Innoviva Inc is $15.17. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

The fundamentals: the financial health trends of Innoviva Inc.
The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Innoviva Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $7.94. Based on the TTM, the Book Value Change Per Share is $-0.05 per quarter. Based on the YOY, the Book Value Change Per Share is $0.42 per quarter.
You may receive quarterly/yearly dividend in the form of additional shares.
You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.

Based on historical numbers we can estimate the returns while holding a share of Innoviva Inc.

How much money are you going to get?

	MRQ		TTM		YOY		5Y		10Y
	$	% of Price per Share	$	% of Price per Share	$	% of Price per Share	$	% of Price per Share	$	% of Price per Share
Usd Eps	0.72	4.8%	0.52	3.4%	0.49	3.2%	0.51	3.3%	0.34	2.2%
Usd Book Value Change Per Share	0.66	4.3%	-0.05	-0.3%	0.42	2.8%	0.33	2.2%	0.13	0.9%
Usd Dividend Per Share	0.00	0.0%	0.00	0.0%	0.00	0.0%	0.01	0.0%	0.10	0.6%
Usd Total Gains Per Share	0.66	4.3%	-0.05	-0.3%	0.42	2.8%	0.33	2.2%	0.23	1.5%
Usd Price Per Share	16.04	-	13.25	-	14.74	-	13.66	-	14.49	-
Price to Earnings Ratio	5.54	-	44.75	-	100.58	-	34.69	-	19.22	-
Price-to-Total Gains Ratio	24.32	-	3.29	-	181.34	-	50.67	-	59.41	-
Price to Book Ratio	2.02	-	1.78	-	2.29	-	3.08	-	-1.06	-
Price-to-Total Gains Ratio	24.32	-	3.29	-	181.34	-	50.67	-	59.41	-

When do you get the money?

Usd Investment	$.00
Usd Price Per Share	15.17
Number of shares	65

Gains per Quarter	Trailing 12 Months	5 Year
Usd Dividend Per Share	0.00	0.01
Usd Book Value Change Per Share	-0.05	0.33
Usd Total Gains Per Share	-0.05	0.33
Gains per Quarter (65 shares)	-2.93	21.65
Gains per Year (65 shares)	-11.74	86.58

Years	Return on Investment (TTM)			Return on Investment (5Y)
	Dividend	Book Value gain	Total gains	Dividend	Book Value gain	Total gains
Broker costs	-	-	-10	-	-	-10
1	0	-12	-22	2	85	77
2	0	-24	-34	3	170	164
3	0	-35	-46	5	255	251
4	0	-47	-58	6	340	338
5	0	-59	-70	8	425	425
6	0	-71	-82	10	510	512
7	0	-83	-94	11	595	599
8	0	-94	-106	13	680	686
9	1	-106	-118	14	765	773
10	1	-118	-130	16	850	860

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %

	Trailing 12 Months				3Y				5 Year				10 Year				ALLTIME
				%				%				%				%				%
Earnings Per Share	4.0	0.0	0.0	100.0%	11.0	1.0	0.0	91.7%	19.0	1.0	0.0	95.0%	32.0	8.0	0.0	80.0%	33.0	46.0	2.0	40.7%
Book Value Change Per Share	2.0	2.0	0.0	50.0%	8.0	4.0	0.0	66.7%	16.0	4.0	0.0	80.0%	25.0	15.0	0.0	62.5%	35.0	46.0	0.0	43.2%
Dividend per Share	1.0	0.0	3.0	25.0%	1.0	0.0	11.0	8.3%	4.0	0.0	16.0	20.0%	23.0	0.0	17.0	57.5%	23.0	0.0	58.0	28.4%
Total Gains per Share	2.0	2.0	0.0	50.0%	8.0	4.0	0.0	66.7%	16.0	4.0	0.0	80.0%	28.0	12.0	0.0	70.0%	38.0	43.0	0.0	46.9%

Fundamentals of Innoviva Inc

About Innoviva Inc

https://www.inva.com
Biotechnology
112
1350 Old Bayshore Highway, Burlingame, CA, United States, 94010
Google Maps Bing Maps

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Fundamental data was last updated by Penke on 2024-04-11 12:01:03.

Financial Health

Profitability Details

	Compared to previous year	Compared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is less efficient in making profit.

Operating Efficiency Details

	Compared to previous year	Compared to industry
The company is operating very efficient.
The company is efficient in keeping operating costs low.

Liquidity Details

	Compared to previous year	Compared to industry
The company is very able to pay all its short-term debts.
The company is unable to pay all its short-term debts with the most liquid assets.

Solvency Details

	Compared to previous year	Compared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details

	Compared to previous year	Compared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is cheap.

1.1. Profitability of Innoviva Inc.

1.1. Profitability

1.1.1. Net Profit Margin

Measures how much net profit Innoviva Inc earns for each $1 of revenue.

Above 10% is considered healthy but always compare Innoviva Inc to the Biotechnology industry mean.
A Net Profit Margin of 68.9% means that $0.69 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Innoviva Inc:

The MRQ is 68.9%. The company is making a huge profit. +2
The TTM is 59.5%. The company is making a huge profit. +2

Trends

Current period		Compared to		+/-
MRQ	68.9%	TTM	59.5%	+9.4%
TTM	59.5%	YOY	77.3%	-17.8%
TTM	59.5%	5Y	67.1%	-7.6%
5Y	67.1%	10Y	-1,203.5%	+1,270.6%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	68.9%	-200.1%	+269.0%
TTM	59.5%	-216.8%	+276.3%
YOY	77.3%	-288.3%	+365.6%
5Y	67.1%	-449.1%	+516.2%
10Y	-1,203.5%	-605.5%	-598.0%

Measures how much net profit Innoviva Inc earns for each $1 of revenue.

Revenue is the amount of profit Innoviva Inc generates before taxes and all other costs. For example, when you buy a cup of coffee it will cost you $3. The company does not earn $3 in profit but also has to pay various costs and taxes to create that cup of coffee. Let's assume the cost of creating a cup of coffee is $1.5.

The $3 you pay for a cup of coffee is called revenue.
The $1.5 that’s left over when all costs to create that cup of coffee (including taxes) are deduced from the revenue is called net profit.

The net profit margin looks at how much net profit Innoviva Inc earns for each $1 in revenue.

How to use net profit margin

Higher profit margin is better (more profit).
Above 10% is considered healthy but always compare Innoviva Inc to the Biotechnology industry mean.
Can be used to compare companies within the Biotechnology industry.

You typically want a high profit margin. This means that for each $1 in sales, Innoviva Inc makes more profit. This shows the investor how efficiently Innoviva Inc is operating in general and compared to other companies in the same industry. Innoviva Inc operates in the Biotechnology industry.

Why do investors use net profit margin in their analysis

It helps investors to determine the efficiency of Innoviva Inc. If profit margins remain low (compared to the Biotechnology industry mean) and there are no improvements to make in production costs or other areas that might be a warning sign. If profit margins are high that means the company has low overhead costs and is efficiently using its resources to generate profit.

The three steps every investor should look at:

What is the current net profit margin?
The current most recent quarter (MRQ) Net Profit Margin of Innoviva Inc is 0.69. This means that Innoviva Inc earned $0.69 for each $1 in revenue in the most recent quarter.
How does it compare to the industry?
The mean MRQ Net Profit Margin of the Biotechnology industry is -200.1%.
What is the trend?
The trend is important because it shows you how Innoviva Inc is performing over time. The most recent quarter might be important if Innoviva Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Innoviva Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare Innoviva Inc with other companies in the same industry (Biotechnology).
Net profit margin should rise over the years.
Can be influenced when Innoviva Inc sells assets (profit will increase while costs remain the same).
It won’t show what part of Innoviva Inc is doing great or needs improvement (it only looks at total revenue and total net income).

How to calculate net profit margin

Net profit margin = net income / total revenue * 100%

Real example of Innoviva Inc

You need the following data to determine net profit margin:

Income statement from the period you want to calculate (for example, MRQ or TTM).

Net income MRQ Innoviva Inc = 61,531
Total revenue MRQ Innoviva Inc = 89,272
$61,531 / $89,272 = 0.69 or 68.9%

Higher is better

The higher the net profit margin, the more efficient the company is generating income. This helps investors to determine how the company is managing money. The net profit margin is an important indicator when diving into the financial health of a company. Overall, you want to see the net profit margin rising over the years. That means the company improved their production and made it more efficient (if possible).

You can use the net profit margin to compare companies within the same industry. If there are two companies where one is much bigger but the smaller one has a higher net profit margin, that means the smaller company is more efficiently using operational costs.

Important: Profit margins can be very different between industries. Companies with assembly lines or transports are much more prone to see shifting in prices for fuel, ingredients and maintenance compared to companies that only provide services. You should never compare net profit margin between different industries.

1.1.2. Return on Assets

Shows how efficient Innoviva Inc is using its assets to generate profit.

Above 5% is considered healthy but always compare Innoviva Inc to the Biotechnology industry mean.
4.9% Return on Assets means that Innoviva Inc generated $0.05 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Innoviva Inc:

The MRQ is 4.9%. Using its assets, the company is less efficient in making profit.
The TTM is 3.8%. Using its assets, the company is less efficient in making profit.

Trends

Current period		Compared to		+/-
MRQ	4.9%	TTM	3.8%	+1.2%
TTM	3.8%	YOY	4.0%	-0.2%
TTM	3.8%	5Y	5.5%	-1.7%
5Y	5.5%	10Y	5.5%	0.0%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	4.9%	-13.3%	+18.2%
TTM	3.8%	-12.8%	+16.6%
YOY	4.0%	-11.7%	+15.7%
5Y	5.5%	-13.9%	+19.4%
10Y	5.5%	-15.7%	+21.2%

Shows how efficient Innoviva Inc is using its assets to generate profit.

For a farm, a tractor is considered an asset. The tractor helps ploughing the land making it possible to plant and harvest crops. But the tractor might be old and needing maintenance all the time reducing its efficiency. Return on assets indicates how effectively the farm is using the tractor (and other assets that help the core business) to plough the land.

How to use return on assets

Higher is better.
Above 5% is considered healthy but always compare Innoviva Inc to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use return on assets in their analysis

Shows the investor how effectively Innoviva Inc is using its resources to generate profit. If the return on assets (4.9%) from Innoviva Inc are higher than the Biotechnology mean (-13.3%) that means Innoviva Inc is using its resources better than their competitors. If not, that means their competitors are more efficient in using their resources to generate profit.

An investor should always look at:

What is the current return on assets?
The current most recent quarter (MRQ) Return on Assets of Innoviva Inc is 4.9%. This means the company generated $0.05 for each $1 in assets.
How does it compare to the industry?
The mean MRQ Return on Assets of the Biotechnology industry is -13.3%.
What is the trend?
The trend is important because it shows you how Innoviva Inc is performing over time. The most recent quarter might be important if Innoviva Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Innoviva Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
If a company has many assets changing over time, it’s better to calculate the average assets instead of the total assets.

How to calculate return on assets

Return on assets = net income / total assets * 100%

Real example Innoviva Inc

You need the following data to determine return on assets (ROA):

Income statement
Balance sheet

Net income MRQ (income statement) from Innoviva Inc = 61,531
Total assets MRQ (balance sheet) from Innoviva Inc = 1,243,507
61,531 / 1,243,507 = 0.05 or 4.9%

ROA is an important ratio as it will tell you how effectively Innoviva Inc is using its resources to generate profits. Example:

Bob and Kristin both sell ice cream in the summer. They both have an ice cream truck. The truck Bob owes cost him $20.000 and the truck Kristin owes cost her $1500. Over the summer, Bob earned $2000 and Kristin earned $200. To calculate the return on assets:

Bob: $2000 / $20.000 * 100% = 10%
Kristin: $200 / $1500 * 100% = 13.3%

This tells you Bob’s company is more valuable but Kristin's company is more efficient. Be aware that total assets can change over time. A transportation business will buy and sell trucks or planes all the time. Before using return on assets as a guideline, you have to know what the exact assets are. For a company that has many assets changing over time, it’s better to calculate the average assets instead of the total assets.

1.1.3. Return on Equity

Shows how efficient Innoviva Inc is using its investors money to generate profit.

Above 15%-20% is considered healthy but always compare Innoviva Inc to the Biotechnology industry mean.
9.1% Return on Equity means Innoviva Inc generated $0.09 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Innoviva Inc:

The MRQ is 9.1%. Using its investors money, the company is less efficient in making profit.
The TTM is 7.2%. Using its investors money, the company is less efficient in making profit.

Trends

Current period		Compared to		+/-
MRQ	9.1%	TTM	7.2%	+2.0%
TTM	7.2%	YOY	8.4%	-1.3%
TTM	7.2%	5Y	11.9%	-4.8%
5Y	11.9%	10Y	9.6%	+2.3%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	9.1%	-16.9%	+26.0%
TTM	7.2%	-16.1%	+23.3%
YOY	8.4%	-15.1%	+23.5%
5Y	11.9%	-19.3%	+31.2%
10Y	9.6%	-20.2%	+29.8%

Shows how efficient Innoviva Inc is using its investors money to generate profit.

A publicly traded company (any company that issues shares to the public) is owned by its shareholders. Return on equity calculates the amount of profit for every $1 the shareholders invested.

How to use return on equity

Higher is better.
Above 15%-20% is considered healthy but always compare Innoviva Inc to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use return on equity in their analysis

To find out the owners/management's attitude toward their company. You typically want the owners/management to invest in the company and focus on generating profit. If not enough profit is generated (compared to the Biotechnology industry mean), the company might not be investing their money efficiently.

The three steps every investor should look at:

What is the current return on equity?
The current most recent quarter (MRQ) Return on Equity of Innoviva Inc is 9.1%. This means Innoviva Inc generated $0.09 for each $1 the owners (shareholders) invested.
How does it compare to the industry?
The mean MRQ Return on Equity of the Biotechnology industry is -16.9%.
What is the trend?
The trend is important because it shows you how Innoviva Inc is performing over time. The most recent quarter might be important if Innoviva Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Innoviva Inc up to 10 years back (depending if Innoviva Inc existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Does not include intangible assets (non physical assets like licences, computer software, etc.).
Stockholders equity and shareholders equity refer to the same thing.
Liabilities should not be more than three times return on equity.

How to calculate return on equity

Return on equity = net profit / shareholders equity * 100%

Real example of Innoviva Inc

You need the following data to determine ROE:

Income statement
Balance sheet
Net profit MRQ (income statement) Innoviva Inc = 61,531
Shareholders equity (balance sheet) MRQ Innoviva Inc = 674,955
61,531 / 674,955 = 0.09 or 9.1%

A negative shareholder equity is a warning sign. It means the company has more liabilities than assets. It might also mean that the owners did not invest enough money or they are taking money out of the business.

1.2. Operating Efficiency of Innoviva Inc.

1.2. Operating Efficiency

1.2.1. Operating Margin

Measures how efficient Innoviva Inc is operating .

Measures how much profit Innoviva Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
Above 15% is considered healthy but always compare Innoviva Inc to the Biotechnology industry mean.
An Operating Margin of 42.0% means the company generated $0.42 for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Innoviva Inc:

The MRQ is 42.0%. The company is operating very efficient. +2
The TTM is 43.3%. The company is operating very efficient. +2

Trends

Current period		Compared to		+/-
MRQ	42.0%	TTM	43.3%	-1.2%
TTM	43.3%	YOY	26.6%	+16.7%
TTM	43.3%	5Y	69.2%	-26.0%
5Y	69.2%	10Y	-990.0%	+1,059.3%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	42.0%	-296.2%	+338.2%
TTM	43.3%	-232.5%	+275.8%
YOY	26.6%	-298.2%	+324.8%
5Y	69.2%	-492.1%	+561.3%
10Y	-990.0%	-632.4%	-357.6%

Measures how efficient Innoviva Inc is operating .

The more effecient a company creates products or provides services, the more profit it generates.

How to use operating margin

Higher is better
Above 15% is considered healthy but always compare Innoviva Inc to the Biotechnology industry mean.
Can be very different between industries
Can be used to compare companies

Why do investors use operating margin in their analysis

To determine how much profit Innoviva Inc is making from it’s core business.

The three steps every investor should look at:

What is the current net profit margin?
The current most recent quarter (MRQ) Operating Margin of Innoviva Inc is 42.0%. This means that Innoviva Inc earned $0.42 for each $1 in revenue in the most recent quarter.
How does it compare to the industry?
The mean MRQ Operating Margin of the Biotechnology industry is -296.2%.
What is the trend?
The trend is important because it shows you how Innoviva Inc is performing over time. The most recent quarter might be important if Innoviva Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Innoviva Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry
Can be calculated in different ways

How to calculate operating margin

Operating margin = operating earnings / total revenue

Real example of Innoviva Inc

You need the following data to determine operating margin:

Income statement
Operating earnings MRQ Innoviva Inc = 37,525
Total revenue MRQ Innoviva Inc = 89,272
$37,525 / $89,272 = 0.42 or 42.0%

Operating margin is used to calculate how much profit a company makes after variable costs of production but before paying interest and taxes. Some variable costs examples are wages, raw materials, packaging, and transaction fees. The amount of variable costs is different for each company and industry. In general, a higher operating margin is better as this implicates that a company is running efficiently.

For investors, a higher operating margin is a good sign. Although you should always look at operating margin in the long term. If operating margin is fluctuating over the years this might be a sign that things are not running efficiently enough. It’s a way to check how much profit a company is making from its core business.

Operation earnings can be calculated in multiple ways:

Operation earnings = EBIT - non operating income + non operating expense
Operation earnings = Gross profit - operating expense - depreciation and amortisation
Operation earnings = Total revenue - COGS (costs of goods sold) - indirect costs

1.2.2. Operating Ratio

Measures how efficient Innoviva Inc is keeping operating costs low.

Below 1 is considered healthy (always compare to Biotechnology industry mean).
An Operation Ratio of 0.58 means that the operating costs are $0.58 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Innoviva Inc:

The MRQ is 0.580. The company is very efficient in keeping operating costs low. +2
The TTM is 0.642. The company is efficient in keeping operating costs low. +1

Trends

Current period		Compared to		+/-
MRQ	0.580	TTM	0.642	-0.063
TTM	0.642	YOY	0.426	+0.216
TTM	0.642	5Y	0.243	+0.399
5Y	0.243	10Y	11.489	-11.246

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	0.580	3.231	-2.651
TTM	0.642	3.310	-2.668
YOY	0.426	3.890	-3.464
5Y	0.243	5.739	-5.496
10Y	11.489	7.876	+3.613

Measures how efficient Innoviva Inc is keeping operating costs low.

If the operating ratio is below 1 that means the company is making money. The lower the operating ratio, the more efficient the company.

How to use operating ratio

Lower is better.
Below 1 is considered healthy but always compare Innoviva Inc to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use operating ratio in their analysis

Shows if costs of creating products and or services is increasing or decreasing. The lower the operating ratio, the more efficient the company is creating products and services.

The three steps every investor should look at:

What is the current Operatin ratio?
The current most recent quarter (MRQ) Operating Ratio of Innoviva Inc is 58.0%. This means that Innoviva Inc earned $0.58 for each $1 in net sales in the most recent quarter.
How does it compare to the industry?
The mean MRQ Operating Ratio of the Biotechnology industry is 3.23.
What is the trend?
The trend is important because it shows you how Innoviva Inc is performing over time. The most recent quarter might be important if Innoviva Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Innoviva Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
You need COGS to calculate operating ratio which is not always shown in the income statement.
Does not consider debt.

How to calculate operating ratio

Operating ratio = Operating expenses + COGS \ Net sales

Real life example Innoviva Inc

You need the following data to determine operating ratio:

Income statement

COGS is not always specified on the income statement. If so you can use the following calculation:

(cost of revenue + total operating expenses) \ total revenue
(23,124 +28,623) \ 89,272 = 0.58

The operating ratio measures the efficiency of a company at keeping low costs while generating profits from sales. It compares the total operating expenses to the net amount of sales. The total operating expenses exists of:

COGS (materials, labour, rent of facility, repairs)
Operating expenses (legal fees, marketing, wages, rent, maintenance/repairs)

Operating expenses are all the costs the company makes that are not directly tied to the production of the service or product. Where COGS are costs that are directly tied to the production of a product or service.

Do note that COGS is not always available in the income statement. Some companies include COGS in the operating expenses while others list COGS separately. To make it even more confusing, COGS is also known as “costs of sales” and costs of sales is the same as costs of revenue.

The operating ratio tells you how efficient the company is creating its products or services while keeping prices low. In this case, a lower ratio is better. Higher or rising operating ratios might tell you that costs are rising while sales are not improving or staying the same.

1.3. Liquidity of Innoviva Inc.

1.3. Liquidity

1.3.1. Current Ratio

Measures if Innoviva Inc is able to pay off Short-term Debt.

Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
A Current Ratio of 9.03 means the company has $9.03 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Innoviva Inc:

The MRQ is 9.027. The company is very able to pay all its short-term debts. +2
The TTM is 8.360. The company is very able to pay all its short-term debts. +2

Trends

Current period		Compared to		+/-
MRQ	9.027	TTM	8.360	+0.666
TTM	8.360	YOY	12.205	-3.845
TTM	8.360	5Y	54.936	-46.576
5Y	54.936	10Y	37.602	+17.334

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	9.027	3.890	+5.137
TTM	8.360	4.173	+4.187
YOY	12.205	5.344	+6.861
5Y	54.936	6.126	+48.810
10Y	37.602	6.448	+31.154

Measures if Innoviva Inc is able to pay off Short-term Debt.

How to use current ratio

Higher is better
Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
Can be very different between industries
Can be used to compare companies

Why do investors use current ratio in their analysis

Shows if the company can pay of short term debts if needed. A company that can't pay off it's short term debts might get in trouble if they have to pay off their short term debts for whatever reason. For example, markets can change due to global events like covid-19 or the war in Ukraine versus Russia. Because debts are always taken based on future income, it might become troublesome for Innoviva Inc if something happens in the market that will cause sales to plummet.

The three steps every investor should look at:

What is the current current Ratio?
The current most recent quarter (MRQ) Current Ratio of Innoviva Inc is 9.03. This means Innoviva Inc has $9.03 in assets for each $1 in short-term debts.
How does it compare to the industry?
The mean MRQ Current Ratio of the Biotechnology industry is 3.89.
What is the trend?
The trend is important because it shows you how Innoviva Inc is performing over time. The most recent quarter might be important if Innoviva Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Innoviva Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Might be deluded.
Not all assets can always be quickly sold.
Can be manipulated by increasing or decreasing the assets and/or liabilities.

How to calculate current ratio

Current ratio = current assets \ current liabilities

Real life example Innoviva Inc

You need the following data to determine operating ratio:

Balance sheet
Current ratio = current assets \ current liabilities
344,219 \ 38,134) = 9.03

The current ratio measures if Innoviva Inc is able to pay short-term debts (obligations). Short term in this context means all debt obligations that are about to expire within one year. The current ratio incorporates current liabilities and current assets. Current assets are all the assets a company has that are expected to be consumed or sold within standard business operations. You can find the current assets in the balance sheet. They consist of:

Inventory
Accounts receivable
Marketable securities
Prepaid expenses
Cash
Cash equivalents
liquid assets

The current liabilities are short term obligations that are due within one year. These consist of:

Short term debts
Dividends
Income taxes
Short-term debts
Accounts payable
Interest payments

The result shows an investor if Innoviva Inc is able to pay all its short-term debts if they were due all at once. When the result of the above formula is below 1, then Innoviva Inc does not have enough capital after selling all its assets to pay all short-term debts. If the ratio drops far below 1 that might indicate Innoviva Inc is or will be in financial trouble anytime soon.

Although this gives an investor some clues, the current ratio may also be deluded. Because owning assets does not mean the company can easily sell them. Also, Accounts receivable may be quite old (they will probably never pay) which deludes the current ratio. As with all ratios, you should only compare them between the same industries and companies.

1.3.2. Quick Ratio

Measures if Innoviva Inc is able to pay off Short-term Debt but only using the most liquid assets.

Above 1 is considered healthy but always compare Innoviva Inc to the Biotechnology industry mean.
A Quick Ratio of 7.28 means the company can pay off $7.28 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Innoviva Inc:

The MRQ is 7.279. The company is very able to pay all its short-term debts with the most liquid assets. +2
The TTM is -1.487. The company is unable to pay all its short-term debts with the most liquid assets. -2

Trends

Current period		Compared to		+/-
MRQ	7.279	TTM	-1.487	+8.767
TTM	-1.487	YOY	23.949	-25.437
TTM	-1.487	5Y	89.278	-90.765
5Y	89.278	10Y	57.250	+32.027

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	7.279	3.514	+3.765
TTM	-1.487	3.998	-5.485
YOY	23.949	5.380	+18.569
5Y	89.278	6.105	+83.173
10Y	57.250	6.404	+50.846

Measures if Innoviva Inc is able to pay off Short-term Debt but only using the most liquid assets.

How to use quick ratio

Higher is better.
Above 1 is considered healthy but always compare Innoviva Inc to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use quick ratio in their analysis

Shows how fast Innoviva Inc can pay off its short term debts. This shows if Innoviva Inc can survive emergencies due to market changes or other reasons.

The three steps every investor should look at:

What is the current Quick Ratio?
The current most recent quarter (MRQ) quickRatio of Innoviva Inc is 7.28. This means that Innoviva Inc can pay off $7.28 for each $1 in debt (using most liquid assets).
How does it compare to the industry?
The mean MRQ Quick Ratio of the Biotechnology industry is 3.51.
What is the trend?
The trend is important because it shows you how Innoviva Inc is performing over time. The most recent quarter might be important if Innoviva Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Innoviva Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Incorporates only most liquid assets.

How to calculate quick ratio

Quick ratio = cash and equivalents + marketable securities + accounts receivable / current liabilities

Real life example Innoviva Inc

You need the following data to determine operating ratio:

Balance sheet
Quick ratio = cash and short-term investments + short-term investments + netReceivables / total current liabilities
MRQ quick ratio Innoviva Inc: (193,513 + 0 +84,075) / 38,134 = 7.28

The quick ratio measures the same thing as the current ratio, only it uses the most liquid assets a company has. Meaning, the assets that can be sold for cash the easiest and fastest.

As the quick ratio only incorporates the most liquid assets, you should also check the current ratio which also includes less liquid assets. But they may be harder to sell.

1.4. Solvency of Innoviva Inc.

1.3. Liquidity

1.4.1. Debt to Asset Ratio

Measures how much % of Innoviva Inc assets are financed with debt.

Below 1 (100%) is considered healthy but always compare Innoviva Inc to Biotechnology industry mean.
A Debt to Asset Ratio of 0.46 means that Innoviva Inc assets are financed with 45.7% credit (debt) and the remaining percentage (100% - 45.7%) is financed by its owners/shareholders.

Let's take a look of the Debt to Asset Ratio trends of Innoviva Inc:

The MRQ is 0.457. The company is very able to pay all its debts by selling its assets. +2
The TTM is 0.484. The company is very able to pay all its debts by selling its assets. +2

Trends

Current period		Compared to		+/-
MRQ	0.457	TTM	0.484	-0.027
TTM	0.484	YOY	0.515	-0.032
TTM	0.484	5Y	0.493	-0.009
5Y	0.493	10Y	1.031	-0.538

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	0.457	0.339	+0.118
TTM	0.484	0.336	+0.148
YOY	0.515	0.271	+0.244
5Y	0.493	0.366	+0.127
10Y	1.031	0.389	+0.642

Measures how much % of Innoviva Inc assets are financed with debt.

When there are more debts than assets, that means creditors have a larger stake Innoviva Inc than its shareholders.

How to use debt to asset ratio

Lower is better.
below 1 (100%) is considered healthy but always compare Innoviva Inc to Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use the debt to asset ratio in their analysis

It shows how much debt the company used to finance its assets. If a company is almost entirely financed with debt that means the company might get into serious trouble when emergencies arise like a raise in interest.

The three steps every investor should look at:

What is the current debt to asset ratio?
The current most recent quarter (MRQ) Debt to Asset Ratio of Innoviva Inc is 0.46. This means means that Innoviva Inc is financed with 45.7% credit and the remaining percentage is financed by it's owners (shareholders).
How does it compare to the industry?
The mean MRQ Current Ratio of the Biotechnology industry is 389.0%.
What is the trend?
The trend is important because it shows you how Innoviva Inc is performing over time. The most recent quarter might be important if Innoviva Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Innoviva Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry
Some companies can have higher debt to assets ratio's (for example, banks).
Debt to asset ratio should improve over the years.
If the debt to asset ratio is above 1, look at the industry mean and find out why Innoviva Inc has so much debt.

How to calculate debt to asset ratio

Debt to asset ratio = total debt \ total assets

Real life example Innoviva Inc

You need the following data to determine debt to asset ratio:

Balance sheet
Debt to asset ratio = total debt \ total assets
568,552 \ 1,243,507 = 45.7% or 0.46.

The debt to total assets ratio shows if the company is owned by creditors or shareholders. Or in other words, the total debt in relation to the total amount of assets. It shows how much debt the company used to finance its assets.

1.4.2. Debt to Equity Ratio

Measures if Innoviva Inc is able to pay off its debts by using shareholders equity.

Below 2 is considered healthy but always compare Innoviva Inc to the Biotechnology industry mean.
A Debt to Equity ratio of 84.2% means that company has $0.84 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Innoviva Inc:

The MRQ is 0.842. The company is very able to pay all its debts with equity. +2
The TTM is 0.941. The company is very able to pay all its debts with equity. +2

Trends

Current period		Compared to		+/-
MRQ	0.842	TTM	0.941	-0.098
TTM	0.941	YOY	1.289	-0.348
TTM	0.941	5Y	1.128	-0.188
5Y	1.128	10Y	0.660	+0.468

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	0.842	0.388	+0.454
TTM	0.941	0.402	+0.539
YOY	1.289	0.335	+0.954
5Y	1.128	0.426	+0.702
10Y	0.660	0.461	+0.199

Measures if Innoviva Inc is able to pay off its debts by using shareholders equity.

How to use debt to equity ratio

Lower is better.
Below 2 is considered healthy (always use industry average).
Can be very different between industries.
Can be used to compare companies.

Why do investors use the debt to shareholders equity ratio in their analysis

It shows how much debt the company uses to finance their operations. Shareholders equity is whats left over when you subtract total liabilities from total assets. It's another way to meassure how much of Innoviva Inc is financed with debt or own resources.

The three steps every investor should look at:

What is the current debt to equity ratio?
The current most recent quarter (MRQ) quickRatio of Innoviva Inc is 0.84. This means that Innoviva Inc can pay off $0.84 for each $1 in debt.
How does it compare to the industry?
The mean MRQ Quick Ratio of the Biotechnology industry is 0.39.
What is the trend?
The trend is important because it shows you how Innoviva Inc is performing over time. The most recent quarter might be important if Innoviva Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Innoviva Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Not all debt is equally risky (for example, short term risk is less risky).

How to calculate debt to equity ratio

Debt to equity ratio = total debt \ shareholders equity.

Real life example Innoviva Inc

You need the following data to determine equity ratio:

Balance sheet
Debt to equity ratio = total debt \ shareholders equity
568,552 \ 674,955 = 0.84 or 84.2%

Debt to equity measures the total debt versus the total shareholders equity. While the total debts to total assets ratio uses total assets, the debt to equity ratio looks at the total equity of shareholders. Where equity of shareholders are:

Common shares.
Preferred shares.
Retained earnings.

You can find the shareholders' equity in the balance sheet. A ratio between 0,5 and 1,5 is preferred. If the ratio is above 1.5, that would indicate creditors have significantly more stake (debt) in the company than the shareholders. In other words, the company is using a lot of debt to finance their operations.

Not all debt is equally risky. Meaning you can adjust the ratio by including or excluding certain amounts of debt. Short term debts are less risky because they have to be paid back within one year anyway. It’s much easier to plan one year ahead versus five or ten years.

2. Market Valuation of Innoviva Inc

2.1. Earnings Per Share

2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Innoviva Inc generates.

Above 15 is considered overpriced but always compare Innoviva Inc to the Biotechnology industry mean.
A PE ratio of 5.54 means the investor is paying $5.54 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Innoviva Inc:

The EOD is 5.239. Based on the earnings, the company is cheap. +2
The MRQ is 5.539. Based on the earnings, the company is cheap. +2
The TTM is 44.755. Based on the earnings, the company is overpriced. -1

Trends

Current period		Compared to		+/-
EOD	5.239	MRQ	5.539	-0.300
MRQ	5.539	TTM	44.755	-39.216
TTM	44.755	YOY	100.576	-55.821
TTM	44.755	5Y	34.689	+10.066
5Y	34.689	10Y	19.223	+15.467

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
EOD	5.239	-2.264	+7.503
MRQ	5.539	-2.629	+8.168
TTM	44.755	-2.680	+47.435
YOY	100.576	-4.145	+104.721
5Y	34.689	-6.257	+40.946
10Y	19.223	-6.254	+25.477

Measures how much money you pay for each share for every $1 in earnings Innoviva Inc generates.

Indicates if the company’s shares are under or overvalued.

How to use PE ratio

Above 15 is considered overpriced but is hard to determine. Always compare Innoviva Inc to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use PE ratio in their analysis

The PE ratio tells investors the current sentiment in the market for that company. As with every stock, the stock price never shows the real valuation of a company but rather how the market thinks how much the stock is worth.

In other words, the current stock price also incorporates any future earnings or business opportunities in the future. The best example is the stock market crash in 2000. The PE ratio for any internet based company was going through the roof. Only based on the general assumption the internet and all associated businesses would thrive in the future. But this was based on nothing. A business still needs a good product or service to be able to survive. Instead, every investor bought any stock which did something related to the internet. Result: huge market crash.

Many investors were willing to pay premium prices and that was causing the PE ratio to rise. A high PE ratio is a warning sign that investors might be overvaluing a stock based on future earnings.

The three steps every investor should look at:

What is the current PE Ratio?
The current most recent quarter (MRQ) PE Ratio of Innoviva Inc is 5.54. This means the investor is paying $5.54 for every $1 in earnings.
How does it compare to the industry?
The mean MRQ Quick Ratio of the Biotechnology industry is -2.63.
What is the trend?
The trend is important because it shows you how Innoviva Inc is performing over time. The most recent quarter might be important if Innoviva Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Innoviva Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Some industries might have very high or very low PE ratios in general.
PE ratios can be high for several years, it does not mean a sudden collapse is imminent.
Earnings growth is not included in the PE ratio.

How to calculate PE ratio

PE ratio = market value per share \ earnings per share

Real life example Innoviva Inc

You need the following data to determine the PE ratio:

Balance sheet
Income statement

The PE ratio is a very commonly used ratio to determine the value of a company by comparing the current stock price relative to its earnings per share (EPS). Before we can calculate the PE ratio we need to know the EPS. EPS is calculated as follows:

EPS = (net profit - preferred dividends) \ end of period outstanding shares*
Net profit = revenue - expenses
0 \ 84,995 = EPS
PE ratio MRQ = 5.54

* The net profit minus preferred dividends can be found in the incomestatement as netIncomeApplicableToCommonShares.

The PE value helps investors to determine if the current stock price is under or overvalued. It also projects future growth.

In general, a higher PE ratio means that investors predict higher future growth. If the PE ratio is too high, then investors expect way too much future growth the company can never fulfil. This is most likely to happen in faster moving companies like tech companies or automobile companies like Tesla. These are hot and booming markets where investors expect much future growth driven by new technology (electric cars). When looking at the current MRQ (most recent quarter) PE ratio of Tesla ( jan. 2021) it's about 247 while the average in the industry is only 6. That might be a clue that Tesla is trading for way too high prices compared to their current assets and is more based on future growth.

2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Innoviva Inc:

The EOD is 9.737. Based on how much money comes from the company's main activities, the company is cheap. +2
The MRQ is 10.295. Based on how much money comes from the company's main activities, the company is cheap. +2
The TTM is 8.000. Based on how much money comes from the company's main activities, the company is cheap. +2

Trends

Current period		Compared to		+/-
EOD	9.737	MRQ	10.295	-0.558
MRQ	10.295	TTM	8.000	+2.295
TTM	8.000	YOY	13.214	-5.214
TTM	8.000	5Y	7.118	+0.882
5Y	7.118	10Y	7.607	-0.488

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
EOD	9.737	-2.973	+12.710
MRQ	10.295	-3.333	+13.628
TTM	8.000	-3.553	+11.553
YOY	13.214	-5.605	+18.819
5Y	7.118	-8.376	+15.494
10Y	7.607	-8.865	+16.472

2. Book Value per Share

2.3. Price to Book Ratio

Measures if the stock price of Innoviva Inc is to cheap or to expensive compared to its book value.

At or below 1 is considered healthy (always compare to Biotechnology industry mean).
A PB ratio of 2.02 means the investor is paying $2.02 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Innoviva Inc:

The EOD is 1.910. Based on the equity, the company is underpriced. +1
The MRQ is 2.020. Based on the equity, the company is underpriced. +1
The TTM is 1.776. Based on the equity, the company is underpriced. +1

Trends

Current period		Compared to		+/-
EOD	1.910	MRQ	2.020	-0.110
MRQ	2.020	TTM	1.776	+0.244
TTM	1.776	YOY	2.287	-0.511
TTM	1.776	5Y	3.084	-1.308
5Y	3.084	10Y	-1.062	+4.147

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
EOD	1.910	1.896	+0.014
MRQ	2.020	2.115	-0.095
TTM	1.776	2.093	-0.317
YOY	2.287	2.884	-0.597
5Y	3.084	3.542	-0.458
10Y	-1.062	3.916	-4.978

2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Innoviva Inc.

3.1. Institutions holding Innoviva Inc

Institutions are holding 117.625% of the shares of Innoviva Inc.

Date	Name	Total Shares	Total Assets	Current Shares	Change	%
2023-12-31	BlackRock Inc	16.3728	0.0042	10352073	908301	9.618
2023-09-30	Sarissa Capital Management LP	11.5093	12.7331	7277000	0	0
2023-12-31	Vanguard Group Inc	10.6164	0.0024	6712443	-4994	-0.0743
2023-12-31	Putnam Investments LLC	9.9173	0.1328	6270413	8955	0.143
2023-12-31	Dimensional Fund Advisors, Inc.	7.1441	0.0212	4516999	66295	1.4895
2023-12-31	Renaissance Technologies Corp	6.5548	0.1029	4144447	145040	3.6265
2023-12-31	Westfield Capital Management Company, LP	4.1345	0.2444	2614127	569117	27.8295
2023-12-31	State Street Corporation	3.9837	0.002	2518778	150465	6.3533
2023-12-31	Systematic Financial Management LP	3.4256	1.0307	2165911	-36756	-1.6687
2023-12-31	Morgan Stanley - Brokerage Accounts	3.3485	0.003	2117157	1278776	152.5292
2023-12-31	Goldman Sachs Group Inc	3.2632	0.003	2063262	1045412	102.7079
2023-12-31	Pacer Advisors, INC.	2.7346	0.0785	1728984	1727534	119140.2759
2023-12-31	Geode Capital Management, LLC	2.0739	0.0022	1311272	38375	3.0148
2023-12-31	Amvescap Plc.	1.8267	0.0044	1154972	492994	74.4729
2023-12-31	Charles Schwab Investment Management Inc	1.476	0.0038	933259	135456	16.9786
2023-12-31	Assenagon Asset Management SA	1.2814	0.0345	810208	0	0
2023-12-31	Bank of America Corp	1.2606	0.0013	797068	-232	-0.0291
2023-12-31	Northern Trust Corp	1.1406	0.0021	721173	-2555	-0.353
2023-12-31	Deutsche Bank AG	1.138	0.0059	719505	82948	13.0307
2023-09-30	D. E. Shaw & Co LP	1.1239	0.0096	710623	95114	15.4529
Total		94.3259	14.422	59639674	+6700245	+11.2%

3.2. Funds holding Innoviva Inc

Date	Name	Total Shares	Total Assets	Current Shares	Change	%
2023-12-31	Putnam Global Health Care A	8.1571	5.1659	5157531	0	0
2024-03-28	iShares Core S&P Small-Cap ETF	6.0432	0.0725	3820945	5456	0.143
2024-03-28	Pacer US Small Cap Cash Cows 100 ETF	5.3049	0.5254	3354176	11858	0.3548
2024-02-29	Vanguard Total Stock Mkt Idx Inv	3.0472	0.0019	1926684	0	0
2024-02-29	Vanguard Small Cap Index	2.3516	0.0162	1486853	13864	0.9412
2024-03-28	iShares Russell 2000 ETF	2.2453	0.033	1419632	684	0.0482
2023-12-31	Westfield Capital Mgt Co Sm-Cap Gr Eq	1.7682	1.4287	1118006	98370	9.6476
2024-01-31	Harbor Small Cap Growth Instl	1.6794	1.3452	1061828	-56178	-5.0248
2024-02-29	Vanguard Small Cap Value Index Inv	1.6067	0.0292	1015880	4340	0.429
2024-02-29	DFA US Small Cap Value I	1.5694	0.0986	992261	0	0
2024-02-29	Vanguard Institutional Extnd Mkt Idx Tr	1.3417	0.0127	848334	417	0.0492
2024-02-29	DFA US Targeted Value I	1.1005	0.0824	695792	0	0
2024-03-28	Invesco Pharmaceuticals ETF	1.0226	3.4258	646591	0	0
2024-01-31	Fidelity Small Cap Index	0.942	0.0389	595570	10092	1.7237
2023-12-31	Putnam VT Global Health Care IA	0.813	5.186	514045	0	0
2024-03-29	Dimensional US Targeted Value ETF	0.8075	0.0774	510560	0	0
2024-03-28	SPDR® Portfolio S&P 600 Sm Cap ETF	0.8001	0.0733	505892	510	0.1009
2024-03-28	iShares Russell 2000 Value ETF	0.7815	0.0601	494098	-313	-0.0633
2024-02-29	Vanguard Tax-Managed Small Cap Adm	0.6975	0.0758	440992	0	0
2024-02-29	State St Russell Sm/Mid Cp® Indx NL Cl C	0.6629	0.0153	419104	11600	2.8466
Total		42.7423	17.7643	27024774	+100700	+0.4%

3.3. Insider Transactions

Insiders are holding 1.59% of the shares of Innoviva Inc.

Date	Owner	Type	Amount	Price
2023-06-05	Alexander J Denner	BUY	7000	13.04
2023-05-30	Alexander J Denner	BUY	120000	13.01
2023-05-25	Alexander J Denner	BUY	50000	13.09
2023-05-17	Alexander J Denner	BUY	50000	13.07
2023-05-11	Alexander J Denner	BUY	290000	12.34

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Innoviva Inc compared to the Most Recent Quarter (MRQ).

	End of day	+/-	Most Recent Quarter	Trailing 12 Months	+/-	Year-Over-Year	+/-	5 Year	+/-	10 Year	+/-
Book Value Change Per Share	-	-	0.659	-0.045	+107%	0.423	+56%	0.327	+101%	0.130	+405%
Book Value Per Share	-	-	7.941	7.488	+6%	6.655	+19%	5.325	+49%	1.724	+361%
Current Ratio	-	-	9.027	8.360	+8%	12.205	-26%	54.936	-84%	37.602	-76%
Debt To Asset Ratio	-	-	0.457	0.484	-6%	0.515	-11%	0.493	-7%	1.031	-56%
Debt To Equity Ratio	-	-	0.842	0.941	-10%	1.289	-35%	1.128	-25%	0.660	+28%
Dividend Per Share	-	-	0.001	0.000	+300%	-	+100%	0.006	-85%	0.097	-99%
Eps	-	-	0.724	0.521	+39%	0.492	+47%	0.507	+43%	0.339	+114%
Free Cash Flow Per Share	-	-	0.389	0.441	-12%	0.541	-28%	0.633	-38%	0.352	+11%
Free Cash Flow To Equity Per Share	-	-	0.218	-0.050	+123%	0.390	-44%	0.255	-15%	0.067	+225%
Gross Profit Margin	-	-	1.000	1.000	0%	1.003	0%	1.001	0%	1.000	0%
Intrinsic Value_10Y_max	-	-	41.663	-	-	-	-	-	-	-	-
Intrinsic Value_10Y_min	-	-	-6.227	-	-	-	-	-	-	-	-
Intrinsic Value_1Y_max	-	-	2.782	-	-	-	-	-	-	-	-
Intrinsic Value_1Y_min	-	-	1.070	-	-	-	-	-	-	-	-
Intrinsic Value_3Y_max	-	-	9.420	-	-	-	-	-	-	-	-
Intrinsic Value_3Y_min	-	-	1.767	-	-	-	-	-	-	-	-
Intrinsic Value_5Y_max	-	-	17.338	-	-	-	-	-	-	-	-
Intrinsic Value_5Y_min	-	-	0.871	-	-	-	-	-	-	-	-
Market Cap	959158141.000	-42%	1363319800.000	1081595032.500	+26%	1315260520.000	+4%	1331524002.500	+2%	1548337232.750	-12%
Net Profit Margin	-	-	0.689	0.595	+16%	0.773	-11%	0.671	+3%	-12.035	+1846%
Operating Margin	-	-	0.420	0.433	-3%	0.266	+58%	0.692	-39%	-9.900	+2455%
Operating Ratio	-	-	0.580	0.642	-10%	0.426	+36%	0.243	+138%	11.489	-95%
Pb Ratio	1.910	-6%	2.020	1.776	+14%	2.287	-12%	3.084	-35%	-1.062	+153%
Pe Ratio	5.239	-6%	5.539	44.755	-88%	100.576	-94%	34.689	-84%	19.223	-71%
Price Per Share	15.170	-6%	16.040	13.253	+21%	14.743	+9%	13.659	+17%	14.489	+11%
Price To Free Cash Flow Ratio	9.737	-6%	10.295	8.000	+29%	13.214	-22%	7.118	+45%	7.607	+35%
Price To Total Gains Ratio	23.003	-6%	24.322	3.287	+640%	181.343	-87%	50.668	-52%	59.412	-59%
Quick Ratio	-	-	7.279	-1.487	+120%	23.949	-70%	89.278	-92%	57.250	-87%
Return On Assets	-	-	0.049	0.038	+31%	0.040	+24%	0.055	-10%	0.055	-10%
Return On Equity	-	-	0.091	0.072	+27%	0.084	+8%	0.119	-24%	0.096	-5%
Total Gains Per Share	-	-	0.659	-0.045	+107%	0.423	+56%	0.333	+98%	0.228	+190%
Usd Book Value	-	-	674955000.000	604757000.000	+12%	581208750.000	+16%	498297150.000	+35%	138639025.000	+387%
Usd Book Value Change Per Share	-	-	0.659	-0.045	+107%	0.423	+56%	0.327	+101%	0.130	+405%
Usd Book Value Per Share	-	-	7.941	7.488	+6%	6.655	+19%	5.325	+49%	1.724	+361%
Usd Dividend Per Share	-	-	0.001	0.000	+300%	-	+100%	0.006	-85%	0.097	-99%
Usd Eps	-	-	0.724	0.521	+39%	0.492	+47%	0.507	+43%	0.339	+114%
Usd Free Cash Flow	-	-	33105000.000	35163250.000	-6%	50414750.000	-34%	62719450.000	-47%	35852150.000	-8%
Usd Free Cash Flow Per Share	-	-	0.389	0.441	-12%	0.541	-28%	0.633	-38%	0.352	+11%
Usd Free Cash Flow To Equity Per Share	-	-	0.218	-0.050	+123%	0.390	-44%	0.255	-15%	0.067	+225%
Usd Market Cap	959158141.000	-42%	1363319800.000	1081595032.500	+26%	1315260520.000	+4%	1331524002.500	+2%	1548337232.750	-12%
Usd Price Per Share	15.170	-6%	16.040	13.253	+21%	14.743	+9%	13.659	+17%	14.489	+11%
Usd Profit	-	-	61531000.000	44930500.000	+37%	53480250.000	+15%	52059350.000	+18%	36067425.000	+71%
Usd Revenue	-	-	89272000.000	78473750.000	+14%	82834750.000	+8%	81745500.000	+9%	57750675.000	+55%
Usd Total Gains Per Share	-	-	0.659	-0.045	+107%	0.423	+56%	0.333	+98%	0.228	+190%
	EOD	+4 -4	MRQ	TTM	+28 -7	YOY	+24 -12	5Y	+19 -17	10Y	+21 -15

4.2. Fundamental Score

Let's check the fundamental score of Innoviva Inc based on Penke's default stock scanner.

Penke's Stock Scanner

Indicator	Condition		Value
Price to Earnings Ratio (EOD)	Between	0-15	5.239
Price to Book Ratio (EOD)	Between	0-1	1.910
Net Profit Margin (MRQ)	Greater than	0	0.689
Operating Margin (MRQ)	Greater than	0	0.420
Quick Ratio (MRQ)	Greater than	1	7.279
Current Ratio (MRQ)	Greater than	1	9.027
Debt to Asset Ratio (MRQ)	Less than	1	0.457
Debt to Equity Ratio (MRQ)	Less than	1	0.842
Return on Equity (MRQ)	Greater than	0.15	0.091
Return on Assets (MRQ)	Greater than	0.05	0.049
Total			7/10 (70.0%)

Create your own Stock Scanner

Investing is personal. The best investors buy stocks based on their own analysis. Create your personal Stock Scanner with the key performance indicators that are important to you.
Create your own Stock Scanner

4.3. Technical Score

Let's check the technical score of Innoviva Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

Indicator	Condition		Value
Rsi	Greater than	50	59.226
Ma 20	Greater than	Ma 50	14.807
Ma 50	Greater than	Ma 100	15.050
Ma 100	Greater than	Ma 200	15.460
Open	Greater than	Close	14.950
Total			2/5 (40.0%)

Create your own Symbol Scanner

Trading is personal. The best traders buy and sell based on their own technical analysis. Create your personal Symbol Scanner with the technical indicators that are important to you.
Create your own Symbol Scanner

Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

	2022-12-31		2023-03-31		2023-06-30		2023-09-30		2023-12-31
Reconciled Depreciation	4,070	-265	3,805	4,628	8,433	1,561	9,994	-13,921	-3,927
Tax Provision	3,626	2,649	6,275	-1,750	4,525	-619	3,906	-4,236	-330
Income Tax Expense	3,626	2,649	6,275	-1,750	4,525	-619	3,906	-4,236	-330

Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary

Total Assets	1,243,507
Total Liabilities	568,552
Total Stockholder Equity	674,955

	As reported
Total Liabilities	568,552
Total Stockholder Equity	+ 674,955
Total Assets	= 1,243,507

Assets

Total Assets	1,243,507
Total Current Assets	344,219
Long-term Assets	899,288

Total Current Assets

Total Current Assets (as reported)	344,219
Cash And Cash Equivalents	193,513
Net Receivables	84,075
Inventory	40,737
Other Current Assets	25,894
Total Current Assets (calculated)	344,219
+/-	0

Long-term Assets

Long-term Assets (as reported)	899,288
Property Plant Equipment	3,019
Goodwill	17,905
Long Term Investments	560,978
Intangible Assets	230,335
Long-term Assets Other	735,080
Long-term Assets (calculated)	1,547,317
+/-	648,029

Liabilities & Shareholders' Equity

Total Current Liabilities	38,134
Long-term Liabilities	530,418
Total Stockholder Equity	674,955

Total Current Liabilities

Total Current Liabilities (as reported)	38,134
Short-term Debt	1,207
Accounts payable	6,717
Other Current Liabilities	28,933
Total Current Liabilities (calculated)	36,857
+/-	1,277

Long-term Liabilities

Long-term Liabilities (as reported)	530,418
Long term Debt	446,234
Capital Lease Obligations	2,842
Long-term Liabilities Other	359
Long-term Liabilities (calculated)	449,435
+/-	80,983

Total Stockholder Equity

Total Stockholder Equity (as reported)	674,955
Common Stock	633
Retained Earnings	-25,189
Other Stockholders Equity	699,511
Total Stockholder Equity (calculated)	674,955
+/-	0

Other

Capital Stock	633
Cash and Short Term Investments	193,513
Common Stock Shares Outstanding	84,995
Current Deferred Revenue	1,277
Liabilities and Stockholders Equity	1,243,507
Net Debt	255,563
Net Invested Capital	1,121,189
Net Working Capital	306,085
Property Plant and Equipment Gross	3,019
Short Long Term Debt Total	449,076

Balance Sheet

Currency in USD. All numbers in thousands.

Trend

2023-12-31

2023-09-30

2023-06-30

2023-03-31

2022-12-31

2022-09-30

2022-06-30

2022-03-31

2021-12-31

2021-09-30

2021-06-30

2021-03-31

2020-12-31

2020-09-30

2020-06-30

2020-03-31

2019-12-31

2019-09-30

2019-06-30

2019-03-31

2018-12-31

2018-09-30

2018-06-30

2018-03-31

2017-12-31

2017-09-30

2017-06-30

2017-03-31

2016-12-31

2016-09-30

2016-06-30

2016-03-31

2015-12-31

2015-09-30

2015-06-30

2015-03-31

2014-12-31

2014-09-30

2014-06-30

2014-03-31

2013-12-31

2013-09-30

2013-06-30

2013-03-31

2012-12-31

2012-09-30

2012-06-30

2012-03-31

2011-12-31

2011-09-30

2011-06-30

2011-03-31

2010-12-31

2010-09-30

2010-06-30

2010-03-31

2009-12-31

2009-09-30

2009-06-30

2009-03-31

2008-12-31

2008-09-30

2008-06-30

2008-03-31

2007-12-31

2007-09-30

2007-06-30

2007-03-31

2006-12-31

2006-09-30

2006-06-30

2006-03-31

2005-12-31

2005-09-30

2005-06-30

2005-03-31

2004-12-31

2004-09-30

2004-06-30

2003-12-31

2002-12-31

> Total Assets

192,715
125,449
219,001
204,974
286,022
259,196
233,801
196,988
224,835
327,334
318,897
292,350
262,424
247,659
208,008
198,623
161,983
299,515
281,390
255,262
236,156
214,792
206,085
183,472
181,393
249,930
232,449
212,580
331,202
315,108
303,120
283,325
258,782
217,727
399,422
383,943
368,582
591,519
594,704
666,016
681,255
605,034
605,610
553,713
521,654
488,699
462,086
437,631
424,072
387,829
378,109
370,542
378,996
391,872
372,023
390,972
367,337
276,745
338,692
277,693
548,193
590,114
642,307
675,953
724,826
788,011
879,619
922,256
999,570
1,088,290
789,150
887,239
926,395
1,107,474
1,137,639
1,327,712
1,231,497
1,129,768
1,118,241
1,188,104
1,243,507

1,243,507

1,188,104

1,118,241

1,129,768

1,231,497

1,327,712

1,137,639

1,107,474

926,395

887,239

789,150

1,088,290

999,570

922,256

879,619

788,011

724,826

675,953

642,307

590,114

548,193

277,693

338,692

276,745

367,337

390,972

372,023

391,872

378,996

370,542

378,109

387,829

424,072

437,631

462,086

488,699

521,654

553,713

605,610

605,034

681,255

666,016

594,704

591,519

368,582

383,943

399,422

217,727

258,782

283,325

303,120

315,108

331,202

212,580

232,449

249,930

181,393

183,472

206,085

214,792

236,156

255,262

281,390

299,515

161,983

198,623

208,008

247,659

262,424

292,350

318,897

327,334

224,835

196,988

233,801

259,196

286,022

204,974

219,001

125,449

192,715

> Total Current Assets

0
0
191,656
182,291
264,468
238,506
213,248
177,011
166,818
266,916
247,507
227,385
207,167
190,685
156,926
144,436
134,087
268,380
252,491
227,727
209,961
189,900
184,473
162,870
162,042
232,149
216,223
197,487
316,354
300,272
288,625
269,165
244,763
204,327
386,588
282,535
261,133
474,512
457,233
522,341
483,198
389,196
353,163
273,471
252,182
266,324
243,957
223,754
214,325
196,706
190,421
186,121
198,046
214,418
198,064
220,509
199,615
112,295
178,660
121,129
199,043
251,519
317,685
366,795
431,234
466,907
500,193
572,041
342,058
372,933
148,261
236,928
313,673
317,823
400,328
371,878
443,511
296,446
323,538
304,999
344,219

344,219

304,999

323,538

296,446

443,511

371,878

400,328

317,823

313,673

236,928

148,261

372,933

342,058

572,041

500,193

466,907

431,234

366,795

317,685

251,519

199,043

121,129

178,660

112,295

199,615

220,509

198,064

214,418

198,046

186,121

190,421

196,706

214,325

223,754

243,957

266,324

252,182

273,471

353,163

389,196

483,198

522,341

457,233

474,512

261,133

282,535

386,588

204,327

244,763

269,165

288,625

300,272

316,354

197,487

216,223

232,149

162,042

162,870

184,473

189,900

209,961

227,727

252,491

268,380

134,087

144,436

156,926

190,685

207,167

227,385

247,507

266,916

166,818

177,011

213,248

238,506

264,468

182,291

191,656

Cash And Cash Equivalents

108,796
35,748
106,288
38,004
101,411
85,499
63,879
22,359
49,787
103,522
84,898
85,730
72,388
77,152
45,545
78,860
86,433
81,283
87,610
128,966
92,280
72,918
61,098
65,589
47,544
109,923
69,721
63,101
163,333
147,874
90,658
62,736
44,778
14,310
161,096
112,235
94,849
266,070
199,243
171,892
143,510
125,275
208,052
119,575
96,800
141,186
149,579
78,746
159,180
151,778
112,945
93,194
118,016
159,808
127,634
138,417
73,336
27,138
87,226
48,615
62,417
65,151
141,952
172,946
278,096
351,981
413,147
479,193
246,487
282,890
43,265
135,115
201,525
216,802
283,580
300,789
291,049
144,049
173,025
179,997
193,513

193,513

179,997

173,025

144,049

291,049

300,789

283,580

216,802

201,525

135,115

43,265

282,890

246,487

479,193

413,147

351,981

278,096

172,946

141,952

65,151

62,417

48,615

87,226

27,138

73,336

138,417

127,634

159,808

118,016

93,194

112,945

151,778

159,180

78,746

149,579

141,186

96,800

119,575

208,052

125,275

143,510

171,892

199,243

266,070

94,849

112,235

161,096

14,310

44,778

62,736

90,658

147,874

163,333

63,101

69,721

109,923

47,544

65,589

61,098

72,918

92,280

128,966

87,610

81,283

86,433

78,860

45,545

77,152

72,388

85,730

84,898

103,522

49,787

22,359

63,879

85,499

101,411

38,004

106,288

35,748

108,796

Short-term Investments

39,754
53,404
81,722
136,334
155,730
146,333
138,499
149,964
112,138
155,073
157,543
137,525
128,692
107,482
105,107
58,678
40,383
176,384
144,737
89,871
108,325
105,958
114,585
88,640
107,846
115,525
140,972
129,367
146,301
145,945
193,229
202,433
196,137
185,854
134,393
161,209
153,640
192,986
243,768
334,261
321,615
245,648
126,424
143,536
143,698
109,954
79,684
127,446
28,103
16,414
40,921
55,772
32,417
10,003
7,992
29,775
55,739
29,322
20,316
6,865
52,491
127,027
107,711
124,255
72,749
31,970
3,999
111,745
438,258
519,325
473,677
507,116
483,845
544,437
0
282
403,013
-400,894
-397,940
-422,491
0

-422,491

-397,940

-400,894

403,013

282

544,437

483,845

507,116

473,677

519,325

438,258

111,745

3,999

31,970

72,749

124,255

107,711

127,027

52,491

6,865

20,316

29,322

55,739

29,775

7,992

10,003

32,417

55,772

40,921

16,414

28,103

127,446

79,684

109,954

143,698

143,536

126,424

245,648

321,615

334,261

243,768

192,986

153,640

161,209

134,393

185,854

196,137

202,433

193,229

145,945

146,301

129,367

140,972

115,525

107,846

88,640

114,585

105,958

108,325

89,871

144,737

176,384

40,383

58,678

105,107

107,482

128,692

137,525

157,543

155,073

112,138

149,964

138,499

146,333

155,730

136,334

81,722

53,404

39,754

Net Receivables

0
0
108
1,527
2,124
1,548
6,287
953
990
4,032
417
272
1,726
246
593
535
539
750
10,533
542
553
448
475
368
418
464
467
716
725
702
232
148
323
263
194
171
1,164
2,217
2,373
3,079
3,380
868
3,473
4,012
10,550
10,239
13,997
16,947
26,228
27,539
35,817
36,621
46,847
43,727
61,796
51,878
70,540
55,835
70,542
65,136
83,286
58,639
67,563
69,211
79,427
82,134
82,402
92,150
93,931
88,974
104,262
101,271
110,711
93,515
111,676
6,743
64,073
75,804
80,996
67,766
84,075

84,075

67,766

80,996

75,804

64,073

6,743

111,676

93,515

110,711

101,271

104,262

88,974

93,931

92,150

82,402

82,134

79,427

69,211

67,563

58,639

83,286

65,136

70,542

55,835

70,540

51,878

61,796

43,727

46,847

36,621

35,817

27,539

26,228

16,947

13,997

10,239

10,550

4,012

3,473

868

3,380

3,079

2,373

2,217

1,164

171

194

263

323

148

232

702

725

716

467

464

418

368

475

448

553

542

10,533

750

539

535

593

246

1,726

272

417

4,032

990

953

6,287

1,548

2,124

1,527

108

Inventory

0
0
0
0
0
0
0
0
0
4,051
4,471
0
0
0
2,800
3,800
4,400
5,200
5,500
5,500
5,600
5,600
5,700
6,100
3,400
3,500
2,500
1,700
1,700
1,700
500
500
0
0
4,299
5,148
7,514
8,049
8,240
9,038
10,406
11,014
14,232
5,600
0
-10,239
-13,997
-16,947
-26,228
-27,539
-35,817
-36,621
-46,847
-43,727
-61,796
-51,878
-754
-950
0
0
-83,286
0
-67,563
0
-79,427
0
0
0
-93,931
0
-104,262
0
-110,711
-93,515
3,953
70,807
55,897
49,653
46,846
40,515
40,737

40,737

40,515

46,846

49,653

55,897

70,807

3,953

-93,515

-110,711

-104,262

-93,931

-79,427

-67,563

-83,286

-950

-754

-51,878

-61,796

-43,727

-46,847

-36,621

-35,817

-27,539

-26,228

-16,947

-13,997

-10,239

5,600

14,232

11,014

10,406

9,038

8,240

8,049

7,514

5,148

4,299

500

1,700

2,500

3,500

3,400

6,100

5,700

5,600

5,500

5,200

4,400

3,800

2,800

4,471

4,051

> Long-term Assets

0
0
27,345
22,683
21,554
20,690
20,553
19,977
58,017
60,418
71,390
64,965
55,257
56,974
51,082
54,187
27,896
31,135
28,899
27,535
26,195
24,892
21,612
20,602
19,351
17,781
16,226
15,093
14,848
14,836
14,495
14,160
14,019
13,400
12,834
101,408
107,449
117,007
137,471
143,675
198,057
215,838
252,447
280,242
269,472
222,375
218,129
213,877
209,747
191,123
187,688
184,421
180,950
177,454
173,959
170,463
167,722
164,450
160,032
156,564
349,150
338,595
324,622
309,158
293,592
321,104
379,426
350,215
657,512
715,357
640,889
650,311
612,722
789,651
737,311
278,328
787,986
833,322
794,703
883,105
899,288

899,288

883,105

794,703

833,322

787,986

278,328

737,311

789,651

612,722

650,311

640,889

715,357

657,512

350,215

379,426

321,104

293,592

309,158

324,622

338,595

349,150

156,564

160,032

164,450

167,722

170,463

173,959

177,454

180,950

184,421

187,688

191,123

209,747

213,877

218,129

222,375

269,472

280,242

252,447

215,838

198,057

143,675

137,471

117,007

107,449

101,408

12,834

13,400

14,019

14,160

14,495

14,836

14,848

15,093

16,226

17,781

19,351

20,602

21,612

24,892

26,195

27,535

28,899

31,135

27,896

54,187

51,082

56,974

55,257

64,965

71,390

60,418

58,017

19,977

20,553

20,690

21,554

22,683

27,345

Property Plant Equipment

20,267
15,815
14,001
13,831
13,242
13,395
13,631
13,062
13,180
13,419
13,413
14,281
15,101
16,183
18,698
19,847
20,091
19,480
18,481
17,328
16,206
15,233
14,712
13,910
12,927
11,881
11,049
10,253
10,215
10,548
10,334
10,206
10,372
10,059
9,660
9,579
9,154
9,010
8,952
8,563
10,238
9,734
0
64
324
303
276
248
221
193
174
381
368
328
289
249
209
197
185
173
160
1,569
1,484
24
33
42
37
33
28
24
19
15
12
3,985
3,721
3,844
3,435
3,153
2,880
3,189
3,019

3,019

3,189

2,880

3,153

3,435

3,844

3,721

3,985

1,484

1,569

160

173

185

197

209

249

289

328

368

381

174

193

221

248

276

303

324

9,734

10,238

8,563

8,952

9,010

9,154

9,579

9,660

10,059

10,372

10,206

10,334

10,548

10,215

10,253

11,049

11,881

12,927

13,910

14,712

15,233

16,206

17,328

18,481

19,480

20,091

19,847

18,698

16,183

15,101

14,281

13,413

13,419

13,180

13,062

13,631

13,395

13,242

13,831

14,001

15,815

20,267

Goodwill

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,844
5,544
15,995
26,713
27,946
14,882
17,905
17,905

17,905

14,882

27,946

26,713

15,995

5,544

1,844

Long Term Investments

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
340
340
240
140
83,208
88,962
95,194
99,342
90,314
88,333
55,374
59,831
34,349
47,752
42,856
3,932
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
46,915
128,613
111,745
438,258
519,325
473,677
507,116
483,845
544,437
494,097
489,111
403,013
400,894
433,001
529,531
560,978

560,978

529,531

433,001

400,894

403,013

489,111

494,097

544,437

483,845

507,116

473,677

519,325

438,258

111,745

128,613

46,915

3,932

42,856

47,752

34,349

59,831

55,374

88,333

90,314

99,342

95,194

88,962

83,208

140

240

340

Intangible Assets

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
30,000
40,000
124,257
137,477
194,880
211,646
208,191
204,735
201,279
197,824
194,368
190,912
187,456
184,000
180,545
177,089
173,633
170,177
166,722
163,266
159,810
156,354
152,899
149,443
145,987
142,531
139,076
135,620
0
0
0
0
0
0
0
108,700
105,000
258,489
252,919
248,314
243,356
236,845
230,335

230,335

236,845

243,356

248,314

252,919

258,489

105,000

108,700

135,620

139,076

142,531

145,987

149,443

152,899

156,354

159,810

163,266

166,722

170,177

173,633

177,089

180,545

184,000

187,456

190,912

194,368

197,824

201,279

204,735

208,191

211,646

194,880

137,477

124,257

40,000

30,000

Long-term Assets Other

0
0
13,344
8,852
8,312
7,295
6,922
6,915
6,837
6,999
6,977
6,684
6,156
5,791
5,384
5,340
5,805
10,655
10,418
10,207
9,989
9,659
6,900
6,692
6,424
5,900
5,177
4,840
4,633
4,288
4,161
3,954
3,647
3,341
-80,034
2,867
3,101
8,655
8,205
6,779
8,188
8,796
23,218
20,780
226,292
218,140
217,853
213,629
209,526
190,930
187,514
184,040
180,582
177,126
173,670
170,214
167,513
164,253
159,847
156,391
152,936
149,480
146,024
142,579
139,388
288
264
239
214
188
162
136
108
108,287
105,675
-489,111
101,906
98,044
94,257
90,683
735,080

735,080

90,683

94,257

98,044

101,906

-489,111

105,675

108,287

108

136

162

188

214

239

264

288

139,388

142,579

146,024

149,480

152,936

156,391

159,847

164,253

167,513

170,214

173,670

177,126

180,582

184,040

187,514

190,930

209,526

213,629

217,853

218,140

226,292

20,780

23,218

8,796

8,188

6,779

8,205

8,655

3,101

2,867

-80,034

3,341

3,647

3,954

4,161

4,288

4,633

4,840

5,177

5,900

6,424

6,692

6,900

9,659

9,989

10,207

10,418

10,655

5,805

5,340

5,384

5,791

6,156

6,684

6,977

6,999

6,837

6,915

6,922

7,295

8,312

8,852

13,344

Deferred Long Term Asset Charges

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
196,054
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

196,054

> Total Liabilities

57,291
57,657
91,704
96,876
95,655
98,118
99,843
98,811
165,251
169,814
193,290
198,316
199,114
227,315
223,804
239,508
228,247
390,109
393,016
380,414
371,105
359,054
365,546
358,685
370,387
362,959
358,407
353,724
353,622
342,927
340,602
342,477
345,834
211,596
210,166
210,655
213,554
500,008
509,057
335,967
382,133
341,782
793,136
746,849
745,003
748,842
756,078
760,630
766,717
749,798
741,211
738,406
731,987
726,058
668,752
613,933
610,044
489,492
494,056
385,969
389,141
390,171
395,605
392,190
382,710
382,142
386,807
387,384
391,733
391,609
395,405
395,434
400,460
555,257
572,177
686,344
665,709
568,275
563,154
560,611
568,552

568,552

560,611

563,154

568,275

665,709

686,344

572,177

555,257

400,460

395,434

395,405

391,609

391,733

387,384

386,807

382,142

382,710

392,190

395,605

390,171

389,141

385,969

494,056

489,492

610,044

613,933

668,752

726,058

731,987

738,406

741,211

749,798

766,717

760,630

756,078

748,842

745,003

746,849

793,136

341,782

382,133

335,967

509,057

500,008

213,554

210,655

210,166

211,596

345,834

342,477

340,602

342,927

353,622

353,724

358,407

362,959

370,387

358,685

365,546

359,054

371,105

380,414

393,016

390,109

228,247

239,508

223,804

227,315

199,114

198,316

193,290

169,814

165,251

98,811

99,843

98,118

95,655

96,876

91,704

57,657

57,291

> Total Current Liabilities

39,104
20,163
29,648
33,311
35,037
36,013
38,330
40,427
48,173
53,112
54,047
54,801
59,609
62,886
59,802
57,136
55,533
49,720
50,172
43,705
43,955
37,416
40,369
39,341
38,946
35,576
36,004
36,381
40,054
33,419
35,191
39,814
45,496
25,575
25,776
27,090
29,966
29,464
38,646
38,661
84,404
44,144
49,994
36,098
13,756
10,095
11,329
10,393
12,606
9,738
10,478
10,488
11,412
12,885
11,043
6,999
9,742
4,066
6,777
4,299
5,700
3,810
7,475
3,329
5,371
2,798
5,414
3,898
6,110
3,804
5,371
3,125
5,807
13,211
125,908
36,653
38,775
38,137
39,398
36,183
38,134

38,134

36,183

39,398

38,137

38,775

36,653

125,908

13,211

5,807

3,125

5,371

3,804

6,110

3,898

5,414

2,798

5,371

3,329

7,475

3,810

5,700

4,299

6,777

4,066

9,742

6,999

11,043

12,885

11,412

10,488

10,478

9,738

12,606

10,393

11,329

10,095

13,756

36,098

49,994

44,144

84,404

38,661

38,646

29,464

29,966

27,090

25,776

25,575

45,496

39,814

35,191

33,419

40,054

36,381

36,004

35,576

38,946

39,341

40,369

37,416

43,955

43,705

50,172

49,720

55,533

57,136

59,802

62,886

59,609

54,801

54,047

53,112

48,173

40,427

38,330

36,013

35,037

33,311

29,648

20,163

39,104

Short-term Debt

0
0
3,802
3,270
2,621
1,609
1,157
1,062
1,244
1,002
673
539
87
91
94
98
101
105
109
113
117
121
175
181
184
191
195
202
206
200
162
109
69
13
0
0
0
0
0
0
0
0
0
0
725,636
4,411
6,728
5,351
6,208
5,101
3,266
3,551
7,752
6,703
15,181
25,000
25,000
484,591
486,527
0
0
308
317
0
0
0
0
0
25,000
0
0
0
0
96,638
96,759
96,131
97,509
1,266
1,226
1,211
1,207

1,207

1,211

1,226

1,266

97,509

96,131

96,759

96,638

25,000

317

308

486,527

484,591

25,000

15,181

6,703

7,752

3,551

3,266

5,101

6,208

5,351

6,728

4,411

725,636

109

162

200

206

202

195

191

184

181

175

121

117

113

109

105

101

539

673

1,002

1,244

1,062

1,157

1,609

2,621

3,270

3,802

Short Long Term Debt

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
725,636
0
0
0
733,131
3,266
3,266
3,551
7,752
709,028
653,893
25,000
25,000
484,591
486,527
0
0
308
317
0
0
0
0
0
0
0
0
0
0
96,016
96,072
96,131
96,193
0
0
0
0

96,193

96,131

96,072

96,016

317

308

486,527

484,591

25,000

653,893

709,028

7,752

3,551

3,266

733,131

725,636

Accounts payable

1,579
3,199
2,562
3,809
5,925
9,882
8,199
7,781
8,118
11,429
10,493
8,075
16,011
8,818
7,892
5,954
6,957
4,699
3,068
2,527
3,277
1,991
1,823
1,046
1,792
1,999
1,749
1,776
2,128
2,214
2,165
3,699
5,813
5,308
4,989
4,757
5,377
3,525
4,834
5,733
7,583
5,546
1,799
573
10,566
1,025
462
154
818
576
137
528
128
2,304
277
629
601
66
58
109
11
144
1,139
35
10
122
195
623
66
14
30
89
27
1,808
4,323
3,805
2,939
5,933
4,592
3,783
6,717

6,717

3,783

4,592

5,933

2,939

3,805

4,323

1,808

623

195

122

1,139

144

109

601

629

277

2,304

128

528

137

576

818

154

462

1,025

10,566

573

1,799

5,546

7,583

5,733

4,834

3,525

5,377

4,757

4,989

5,308

5,813

3,699

2,165

2,214

2,128

1,776

1,749

1,999

1,792

1,046

1,823

1,991

3,277

2,527

3,068

4,699

6,957

5,954

7,892

8,818

16,011

8,075

10,493

11,429

8,118

7,781

8,199

9,882

5,925

3,809

2,562

3,199

1,579

Other Current Liabilities

9,341
13,492
13,005
15,273
15,532
12,959
16,953
19,563
21,817
23,201
21,429
24,155
24,238
32,756
30,595
28,344
25,956
22,327
22,999
17,069
16,773
14,081
16,345
16,053
13,248
10,585
11,258
11,601
15,798
9,767
12,311
15,119
20,917
14,483
15,016
17,388
19,996
16,058
24,838
23,327
67,532
29,784
47,113
34,443
12,674
3,774
3,254
4,003
4,695
3,176
6,190
5,524
2,647
2,993
-5,300
-19,515
3,822
4,000
6,719
4,190
5,689
3,358
3,213
3,294
5,361
2,676
5,219
3,275
6,044
3,790
5,341
3,036
5,780
-85,235
24,826
-3,805
-63,767
28,844
30,326
29,641
28,933

28,933

29,641

30,326

28,844

-63,767

-3,805

24,826

-85,235

5,780

3,036

5,341

3,790

6,044

3,275

5,219

2,676

5,361

3,294

3,213

3,358

5,689

4,190

6,719

4,000

3,822

-19,515

-5,300

2,993

2,647

5,524

6,190

3,176

4,695

4,003

3,254

3,774

12,674

34,443

47,113

29,784

67,532

23,327

24,838

16,058

19,996

17,388

15,016

14,483

20,917

15,119

12,311

9,767

15,798

11,601

11,258

10,585

13,248

16,053

16,345

14,081

16,773

17,069

22,999

22,327

25,956

28,344

30,595

32,756

24,238

24,155

21,429

23,201

21,817

19,563

16,953

12,959

15,532

15,273

13,005

13,492

9,341

> Long-term Liabilities

0
0
62,056
63,565
60,618
62,105
61,513
58,384
117,078
116,702
139,243
143,515
139,505
164,429
164,002
182,372
172,714
340,389
342,844
336,709
327,150
321,638
325,177
319,344
331,441
327,383
322,403
317,343
313,568
309,508
305,411
302,663
300,338
186,021
184,390
183,565
183,588
470,544
470,411
297,306
297,729
297,638
743,142
710,751
731,247
738,747
744,749
750,237
754,111
740,060
730,733
727,918
720,575
713,173
657,709
606,934
600,302
485,426
487,279
381,670
383,441
386,361
388,130
388,861
377,339
379,344
381,393
383,486
385,623
387,805
390,034
392,309
394,653
542,046
446,269
443,679
626,934
530,138
523,756
524,428
530,418

530,418

524,428

523,756

530,138

626,934

443,679

446,269

542,046

394,653

392,309

390,034

387,805

385,623

383,486

381,393

379,344

377,339

388,861

388,130

386,361

383,441

381,670

487,279

485,426

600,302

606,934

657,709

713,173

720,575

727,918

730,733

740,060

754,111

750,237

744,749

738,747

731,247

710,751

743,142

297,638

297,729

297,306

470,411

470,544

183,588

183,565

184,390

186,021

300,338

302,663

305,411

309,508

313,568

317,343

322,403

327,383

331,441

319,344

325,177

321,638

327,150

336,709

342,844

340,389

172,714

182,372

164,002

164,429

139,505

143,515

139,243

116,702

117,078

58,384

61,513

62,105

60,618

63,565

62,056

Long term Debt Total

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
172,500
172,500
172,500
172,500
172,500
172,500
172,500
460,000
459,960
287,500
287,500
287,500
737,500
705,109
725,636
732,063
738,472
744,085
748,271
734,513
722,287
719,449
708,341
702,325
638,712
578,449
574,362
484,591
486,527
381,002
382,855
384,744
386,675
388,644
377,120
379,152
381,230
383,350
385,517
387,728
389,989
392,295
0
442,731
443,178
443,679
0
444,692
0
0
0

444,692

443,679

443,178

442,731

392,295

389,989

387,728

385,517

383,350

381,230

379,152

377,120

388,644

386,675

384,744

382,855

381,002

486,527

484,591

574,362

578,449

638,712

702,325

708,341

719,449

722,287

734,513

748,271

744,085

738,472

732,063

725,636

705,109

737,500

287,500

459,960

460,000

172,500

Capital Lease Obligations Min Short Term Debt

0
0
-3,802
-3,270
-2,621
-1,609
-1,157
-1,062
-1,244
-1,002
-673
-539
-87
-91
-94
-98
-101
-105
-109
-113
-117
-121
-175
-181
-184
-191
-195
-202
-206
-200
-162
-109
-69
-13
0
0
0
0
0
0
0
0
0
0
-725,636
-4,411
-6,728
-5,351
-6,208
-5,101
-3,266
-3,551
-7,752
-6,703
-15,181
-25,000
-25,000
-484,591
-486,527
0
0
1,238
1,157
0
0
0
0
0
-25,000
0
0
0
0
-93,339
-92,981
-92,258
-93,817
2,101
1,858
1,953
1,635

1,635

1,953

1,858

2,101

-93,817

-92,258

-92,981

-93,339

-25,000

1,157

1,238

-486,527

-484,591

-25,000

-15,181

-6,703

-7,752

-3,551

-3,266

-5,101

-6,208

-5,351

-6,728

-4,411

-725,636

-13

-69

-109

-162

-200

-206

-202

-195

-191

-184

-181

-175

-121

-117

-113

-109

-105

-101

-98

-94

-91

-87

-539

-673

-1,002

-1,244

-1,062

-1,157

-1,609

-2,621

-3,270

-3,802

Deferred Long Term Asset Charges

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
196,054
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

196,054

Long-term Liabilities Other

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,300
1,530
1,718
1,947
1,748
1,847
1,856
1,784
1,639
1,598
1,383
1,267
1,159
1,049
940
835
752
668
586
379
298
217
219
192
163
136
106
77
45
14
0
3,299
3,091
78,421
70,918
70,133
749
595
359

359

595

749

70,133

70,918

78,421

3,091

3,299

106

136

163

192

219

217

298

379

586

668

752

835

940

1,049

1,159

1,267

1,383

1,598

1,639

1,784

1,856

1,847

1,748

1,947

1,718

1,530

1,300

Deferred Long Term Liability

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
132,911
130,163
127,838
13,521
11,890
11,065
11,088
10,544
10,451
9,806
10,229
10,138
4,342
4,112
3,893
3,852
3,644
3,420
3,099
2,878
2,656
2,435
2,214
1,993
1,772
1,551
166,722
163,266
159,810
156,354
152,899
149,443
145,987
142,531
139,076
135,620
132,164
128,708
125,253
121,797
118,341
114,885
111,430
107,974
104,518
101,062
97,607
5,392
0
0
0

5,392

97,607

101,062

104,518

107,974

111,430

114,885

118,341

121,797

125,253

128,708

132,164

135,620

139,076

142,531

145,987

149,443

152,899

156,354

159,810

163,266

166,722

1,551

1,772

1,993

2,214

2,435

2,656

2,878

3,099

3,420

3,644

3,852

3,893

4,112

4,342

10,138

10,229

9,806

10,451

10,544

11,088

11,065

11,890

13,521

127,838

130,163

132,911

> Total Stockholder Equity

135,424
67,792
127,297
108,098
190,367
161,078
133,958
98,177
59,584
157,520
125,607
94,034
63,310
20,344
-15,796
-40,885
-66,264
-90,594
-111,626
-125,152
-134,949
-144,262
-159,461
-175,213
-188,994
-113,029
-125,958
-141,144
-22,420
-27,819
-37,482
-59,152
-87,052
6,131
189,256
173,288
155,028
91,511
85,647
330,049
299,122
263,252
-187,526
-193,136
-223,349
-260,143
-293,992
-322,999
-342,645
-361,969
-363,102
-367,864
-352,991
-334,186
-296,729
-222,961
-242,859
-213,558
-157,356
-111,357
153,583
188,245
226,683
267,055
313,495
379,543
456,907
485,556
539,912
634,461
329,780
402,811
414,743
386,642
388,337
641,368
565,788
561,493
555,087
627,493
674,955

674,955

627,493

555,087

561,493

565,788

641,368

388,337

386,642

414,743

402,811

329,780

634,461

539,912

485,556

456,907

379,543

313,495

267,055

226,683

188,245

153,583

-111,357

-157,356

-213,558

-242,859

-222,961

-296,729

-334,186

-352,991

-367,864

-363,102

-361,969

-342,645

-322,999

-293,992

-260,143

-223,349

-193,136

-187,526

263,252

299,122

330,049

85,647

91,511

155,028

173,288

189,256

6,131

-87,052

-59,152

-37,482

-27,819

-22,420

-141,144

-125,958

-113,029

-188,994

-175,213

-159,461

-144,262

-134,949

-125,152

-111,626

-90,594

-66,264

-40,885

-15,796

20,344

63,310

94,034

125,607

157,520

59,584

98,177

133,958

161,078

190,367

108,098

127,297

67,792

135,424

Common Stock

72
72
453
454
529
531
534
536
538
594
597
599
601
602
606
608
610
610
614
617
619
627
632
636
643
731
736
739
804
816
848
851
855
865
969
979
984
993
1,008
1,105
1,115
1,125
1,133
1,154
1,164
1,169
1,172
1,176
1,149
1,132
1,116
1,098
1,085
1,093
1,094
1,080
1,019
1,014
1,015
1,011
1,011
1,012
1,013
1,013
1,013
1,013
1,015
1,014
1,014
1,014
695
695
696
696
697
698
692
659
653
644
633

633

644

653

659

692

698

697

696

695

1,014

1,015

1,013

1,012

1,011

1,015

1,014

1,019

1,080

1,094

1,093

1,085

1,098

1,116

1,132

1,149

1,176

1,172

1,169

1,164

1,154

1,133

1,125

1,115

1,105

1,008

993

984

979

969

865

855

851

848

816

804

739

736

731

643

636

632

627

619

617

614

610

608

606

602

601

599

597

594

538

536

534

531

529

454

453

Retained Earnings Total Equity

-170,046

-136,597

-402,198

-403,137

-456,148

-466,493

-538,931

-627,879

-722,002

-775,905

-804,123

-880,967

-1,069,902

-1,103,692

-1,367,452

-1,414,541

-1,469,167

-1,498,748

-1,557,133

-1,580,900

-1,616,046

-1,632,891

-1,658,362

-1,673,395

-1,687,992

-1,692,427

-1,696,728

-1,692,144

-1,684,334

-1,673,667

-1,657,741

-1,636,470

-1,572,906

-1,505,203

-1,455,274

-1,408,291

-1,371,862

-1,334,502

-1,303,178

-1,268,486

-1,231,366

-1,315,960

-1,278,953

-1,248,328

Accumulated Other Comprehensive Income

0
0
-14,850
-15,278
-11,256
-10,542
-8,774
-6,911
-5,485
-514
-499
-42
23
80
34
81
57
362
-10
-86
501
327
198
61
35
-18
-26
77
33
28
-8
16
16
-9
-109
116
99
92
-15
202
162
171
3,706
-197
-87
-12
-10
11
-2
-1
6
8
1
-1
0
-3
-18
-22
-10
-3
-3
10
33
25
27
33
-2
0
0
0
0
0
0
0
0
0
0
0
0
0
0

-2

-3

-10

-22

-18

-3

-1

-2

-10

-12

-87

-197

3,706

171

162

202

-15

116

-109

-9

-8

-26

-18

198

327

501

-86

-10

362

-42

-499

-514

-5,485

-6,911

-8,774

-10,542

-11,256

-15,278

-14,850

Capital Surplus

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,210,006
1,218,934
1,228,037
1,236,641
1,456,882
1,475,371
1,488,447
1,462,288
1,492,945
1,784,016
1,803,048
1,834,862
1,444,105
1,466,911
1,452,504
1,426,297
1,400,253
1,375,805
1,351,898
1,328,155
1,312,434
1,292,655
1,282,077
1,284,031
1,286,340
1,336,358
1,258,151
1,257,880
1,259,443
1,258,350
1,256,267
1,257,125
1,257,799
1,258,370
1,258,859
1,259,464
1,260,017
1,260,447
1,260,900
1,261,326
1,261,845
1,262,438
1,264,024
1,182,912
1,183,667
1,171,096
0
1,124,709
0
0
0

1,124,709

1,171,096

1,183,667

1,182,912

1,264,024

1,262,438

1,261,845

1,261,326

1,260,900

1,260,447

1,260,017

1,259,464

1,258,859

1,258,370

1,257,799

1,257,125

1,256,267

1,258,350

1,259,443

1,257,880

1,258,151

1,336,358

1,286,340

1,284,031

1,282,077

1,292,655

1,312,434

1,328,155

1,351,898

1,375,805

1,400,253

1,426,297

1,452,504

1,466,911

1,444,105

1,834,862

1,803,048

1,784,016

1,492,945

1,462,288

1,488,447

1,475,371

1,456,882

1,236,641

1,228,037

1,218,934

1,210,006

Treasury Stock

-3,263

Other Stockholders Equity

0
0
558,839
357,381
669,698
671,144
673,969
674,109
676,299
818,160
827,704
833,452
840,498
846,924
855,951
863,177
870,878
876,007
882,369
889,844
895,383
905,453
912,070
918,634
927,082
1,025,548
1,033,427
1,039,357
1,177,359
1,194,620
1,210,006
1,218,934
1,228,037
1,236,641
1,456,882
1,475,371
1,488,447
1,462,288
1,492,945
1,784,016
1,803,048
1,834,862
1,444,105
1,463,648
1,449,241
1,423,034
1,396,990
1,372,542
1,348,635
1,324,892
1,309,171
1,289,392
1,278,814
1,280,768
1,283,077
1,333,095
1,254,888
1,254,617
1,256,180
1,255,087
1,256,267
1,257,125
1,257,799
1,258,370
1,258,859
1,259,464
1,260,017
1,260,447
1,260,900
1,261,326
868,016
868,609
870,195
789,083
789,838
136,675
770,007
730,880
723,200
713,569
699,511

699,511

713,569

723,200

730,880

770,007

136,675

789,838

789,083

870,195

868,609

868,016

1,261,326

1,260,900

1,260,447

1,260,017

1,259,464

1,258,859

1,258,370

1,257,799

1,257,125

1,256,267

1,255,087

1,256,180

1,254,617

1,254,888

1,333,095

1,283,077

1,280,768

1,278,814

1,289,392

1,309,171

1,324,892

1,348,635

1,372,542

1,396,990

1,423,034

1,449,241

1,463,648

1,444,105

1,834,862

1,803,048

1,784,016

1,492,945

1,462,288

1,488,447

1,475,371

1,456,882

1,236,641

1,228,037

1,218,934

1,210,006

1,194,620

1,177,359

1,039,357

1,033,427

1,025,548

927,082

918,634

912,070

905,453

895,383

889,844

882,369

876,007

870,878

863,177

855,951

846,924

840,498

833,452

827,704

818,160

676,299

674,109

673,969

671,144

669,698

357,381

558,839

Balance Sheet

Currency in USD. All numbers in thousands.

	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31	2005-12-31	2004-12-31	2003-12-31	2002-12-31	2001-12-31	2000-12-31
Accounts Payable	6,717	2,939	27	66	10	11	601	128	818	0	7,583	5,377	5,813	2,128	1,792	3,277	6,957	16,011	8,118	5,925	3,199	1,579	-	-
Accumulated Amortization	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Accumulated Depreciation	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Accumulated Other Comprehensive Income	0	0	0	0	27	-3	-18	1	-2	-87	162	99	16	33	35	501	57	23	-5,485	-11,256	-2,425	-4,341	-	-
Additional Paid In Capital	0	0	0	0	0	0	1,258,151	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Capital Lease Obligations	2,842	3,692	106	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Capital Stock	633	692	696	1,014	1,013	1,011	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Capital Surpluse	0	0	1,264,024	1,260,900	1,258,859	1,256,267	1,258,151	1,282,077	1,351,898	0	1,803,048	1,488,447	1,228,037	0	0	0	0	0	0	0	0	0	-	-
Cash	193,513	291,049	201,525	246,487	278,096	62,417	73,336	118,016	159,180	96,800	143,510	94,849	44,778	163,333	47,544	92,280	86,433	72,388	49,787	101,411	35,748	108,796	-	-
Cash And Equivalents	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Cash And Short Term Investments	193,513	291,049	201,525	246,487	350,845	114,908	129,075	150,433	187,283	240,498	465,125	248,489	240,915	309,634	155,390	200,605	126,816	201,080	161,925	257,141	89,152	148,550	-	-
Common Stock	633	692	696	1,014	1,013	1,011	1,019	1,085	1,149	1,164	1,115	984	855	804	643	619	610	601	538	529	72	72	-	-
Common Stock Shares Outstanding	36,076	34,294	94,310	113,554	113,409	113,408	119,866	123,233	115,372	112,059	102,425	90,909	82,051	72,070	63,027	61,390	60,498	59,013	53,270	33,283	6,809	6,336	5,526	3,807
Common Stock Total Equity	0	0	696	1,014	1,013	1,011	1,019	1,085	1,149	1,164	1,115	984	855	804	643	619	610	601	538	529	72	72	-	-
Current Deferred Revenue	1,277	2,094	-106	0	0	0	-19,681	885	885	1,082	9,289	4,593	18,697	21,922	23,722	23,788	22,519	19,273	16,994	10,959	5,273	1,250	-	-
Deferred Long Term Asset Charges	0	0	0	0	0	196,054	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Deferred Long Term Liab	0	97,607	111,430	125,253	139,076	152,899	166,722	180,545	3,099	208,191	10,229	11,088	127,838	0	0	0	0	0	0	0	0	0	-	-
Earning Assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Good Will	17,905	26,713	101,174	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Intangible Assets	230,335	252,919	10,256	0	139,076	152,899	166,722	180,545	194,368	208,191	124,257	0	0	0	0	0	0	0	0	0	0	0	-	-
Inventory	40,737	55,897	-110,711	-93,931	-79,427	-83,286	-754	-46,847	-26,228	0	10,406	7,514	0	1,700	3,400	5,600	4,400	0	0	0	0	0	-	-
Liabilities And Stockholders Equity	1,243,507	1,231,497	926,395	999,570	724,826	548,193	367,337	378,996	424,072	521,654	681,255	368,582	258,782	331,202	181,393	236,156	161,983	262,424	224,835	286,022	125,449	192,715	-	246,854
Long Term Debt	446,234	540,373	394,653	385,517	377,120	382,855	574,362	708,341	733,131	725,636	287,500	172,500	172,500	172,569	172,775	172,819	435	538	631	1,779	4,398	7,867	-	-
Long Term Debt Total	0	0	0	385,517	377,120	382,855	574,362	708,341	733,131	0	287,500	172,500	172,500	0	0	0	0	0	0	0	0	0	-	-
Long Term Investments	560,978	403,013	483,845	438,258	0	0	0	0	0	42,856	55,374	95,194	240	0	0	0	0	0	0	0	0	0	-	-
Negative Goodwill	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Net Debt	255,563	346,833	193,128	139,030	99,024	320,438	526,026	598,077	589,091	628,836	143,990	77,651	127,791	9,442	125,415	80,656	-85,897	-71,763	-47,912	-97,011	-27,878	-72,745	-	-
Net Invested Capital	1,121,189	1,106,161	809,396	925,429	690,615	536,438	356,503	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Net Receivables	84,075	64,073	110,711	93,931	79,427	83,286	70,540	46,847	26,228	10,550	3,380	1,164	323	725	418	553	539	1,726	990	2,124	408	1,509	-	-
Net Tangible Assets	0	286,156	414,743	539,912	313,495	153,583	-242,859	-352,991	-342,645	-223,673	174,865	155,028	-87,052	0	0	0	0	0	0	0	0	0	-	-
Net Working Capital	306,085	404,736	307,866	335,948	425,863	193,343	165,627	186,634	201,719	238,426	398,794	231,167	199,267	276,300	123,096	166,006	78,554	147,558	118,645	229,431	71,085	112,720	-	-
Non Current Assets Total	899,288	787,986	612,722	657,512	293,592	349,150	167,722	180,950	209,747	269,472	198,057	107,449	14,019	14,848	19,351	26,195	27,896	55,257	58,017	21,554	34,201	40,891	-	-
Non Current Liabilities Other	359	70,918	0	106	219	586	940	1,383	1,856	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Non Current Liabilities Total	530,418	626,934	394,653	385,623	377,339	383,441	600,302	720,575	754,111	731,247	297,729	183,588	300,338	313,568	331,441	327,150	172,714	139,505	117,078	60,618	404,852	385,545	-	-
Non Currrent Assets Other	87,051	101,906	108	214	139,388	152,936	167,513	180,582	209,526	226,292	8,188	3,101	3,647	4,633	6,424	9,989	5,805	6,156	6,837	8,312	18,386	20,624	-	-
Noncontrolling Interest In Consolidated Entity	0	0	111,192	67,925	0	5,469	152	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Other Assets	0	198,471	425,211	657,484	293,559	348,990	166,759	180,582	18	18,101	8,188	3,101	3,647	4,633	6,424	9,989	3,810	3,884	4,257	8,312	18,386	20,624	-	246,854
Other Current Assets	25,894	32,492	112,148	95,571	80,389	84,135	754	47,613	27,042	1,134	4,287	3,966	3,525	5,995	6,234	8,803	6,732	4,361	3,903	5,203	1,688	1,765	-	-
Other Current Liab	28,933	-63,767	5,780	6,044	5,361	5,689	3,822	2,647	4,695	12,674	67,532	19,996	20,917	15,798	13,248	16,773	25,956	24,238	21,817	15,532	8,219	8,091	-	-
Other Liab	0	84,185	0	106	219	586	940	3,597	4,955	5,611	10,229	11,088	127,838	140,999	158,666	154,331	172,279	138,967	116,447	58,839	33,096	10,320	-	-
Other Stockholder Equity	699,511	770,007	870,195	1,260,900	1,258,859	1,256,267	1,254,888	1,278,814	1,348,635	1,449,241	1,803,048	1,488,447	1,228,037	1,177,359	927,082	895,383	870,878	840,498	676,299	383,676	68,737	67,702	-	48,377
Preferred Stock Redeemable	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Preferred Stock Total Equity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	367,358	367,358	-	-
Property Plant And Equipment Gross	3,019	3,435	12	28	33	160	209	368	221	324	10,238	9,154	10,372	10,215	12,927	16,206	20,091	15,101	13,180	13,242	15,815	20,267	-	-
Property Plant And Equipment Net	3,019	3,435	12	28	33	160	209	368	221	324	10,238	9,154	10,372	10,215	12,927	16,206	20,091	15,101	13,180	13,242	15,815	20,267	-	-
Property Plant Equipment	0	3,435	12	28	33	160	209	368	221	324	10,238	9,154	10,372	10,215	12,927	16,206	20,091	15,101	13,180	13,242	15,815	20,267	-	-
Retained Earnings	-25,189	-204,911	-456,148	-722,002	-946,404	-1,103,692	-1,498,748	-1,632,891	-1,692,427	-1,673,667	-1,505,203	-1,334,502	-1,315,960	-1,200,616	-1,116,754	-1,031,452	-937,809	-777,812	-611,768	-468,604	-365,950	-295,367	-	-151,295
Retained Earnings Total Equity	0	0	-456,148	-722,002	0	-1,103,692	-1,498,748	-1,632,891	-1,692,427	0	-1,505,203	-1,334,502	-1,315,960	0	0	0	0	0	0	0	0	0	-	-
Short Long Term Debt	0	96,193	0	0	0	0	25,000	7,752	733,131	725,636	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Short Long Term Debt Total	449,076	637,882	394,653	385,517	377,120	382,855	599,362	716,093	748,271	725,636	287,500	172,500	172,569	172,775	172,959	172,936	536	625	1,875	4,400	7,870	36,051	-	-
Short Term Debt	1,207	97,509	106	25,000	0	0	25,000	7,752	6,208	725,636	0	0	69	206	184	117	101	87	1,244	2,621	3,472	28,184	-	-
Short Term Investments	0	403,013	483,845	438,258	72,749	52,491	55,739	32,417	28,103	143,698	321,615	153,640	196,137	146,301	107,846	108,325	40,383	128,692	112,138	155,730	53,404	39,754	-	-
Temporary Equity Redeemable Noncontrolling Interests	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Total Assets	1,243,507	1,231,497	926,395	999,570	724,826	548,193	367,337	378,996	424,072	521,654	681,255	368,582	258,782	331,202	181,393	236,156	161,983	262,424	224,835	286,022	125,449	192,715	-	246,854
Total Current Assets	344,219	443,511	313,673	342,058	431,234	199,043	199,615	198,046	214,325	252,182	483,198	261,133	244,763	316,354	162,042	209,961	134,087	207,167	166,818	264,468	91,248	151,824	-	-
Total Current Liabilities	38,134	38,775	5,807	6,110	5,371	5,700	9,742	11,412	12,606	13,756	84,404	29,966	45,496	40,054	38,946	43,955	55,533	59,609	48,173	35,037	20,163	39,104	-	-
Total Liab	568,552	665,709	400,460	391,733	382,710	389,141	610,044	731,987	766,717	745,003	382,133	213,554	345,834	353,622	370,387	371,105	228,247	199,114	165,251	95,655	425,015	424,649	-	22,665
Total Permanent Equity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Total Stockholder Equity	674,955	565,788	414,743	539,912	313,495	153,583	-242,859	-352,991	-342,645	-223,349	299,122	155,028	-87,052	-22,420	-188,994	-134,949	-66,264	63,310	59,584	190,367	-299,566	-231,934	-	224,189
Treasury Stock	0	0	0	0	0	0	-3,263	-3,263	-3,263	-3,263	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Warrants	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-

	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30	2004-06-30	2003-12-31	2002-12-31
Accounts Payable	6,717	3,783	4,592	5,933	2,939	3,805	4,323	1,808	27	89	30	14	66	623	195	122	10	35	1,139	144	11	109	58	66	601	629	277	2,304	128	528	137	576	818	154	462	1,025	10,566	573	1,799	5,546	7,583	5,733	4,834	3,525	5,377	4,757	4,989	5,308	5,813	3,699	2,165	2,214	2,128	1,776	1,749	1,999	1,792	1,046	1,823	1,991	3,277	2,527	3,068	4,699	6,957	5,954	7,892	8,818	16,011	8,075	10,493	11,429	8,118	7,781	8,199	9,882	5,925	3,809	2,562	3,199	1,579
Accumulated Amortization	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Accumulated Depreciation	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Accumulated Other Comprehensive Income	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-2	33	27	25	33	10	-3	-3	-10	-22	-18	-3	0	-1	1	8	6	-1	-2	11	-10	-12	-87	-197	3,706	171	162	202	-15	92	99	116	-109	-9	16	16	-8	28	33	77	-26	-18	35	61	198	327	501	-86	-10	362	57	81	34	80	23	-42	-499	-514	-5,485	-6,911	-8,774	-10,542	-11,256	-15,278	-14,850	0	0
Additional Paid In Capital	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1,258,151	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	2,842	3,164	3,084	3,367	3,692	3,873	3,778	3,299	0	0	0	0	0	0	0	0	0	0	1,474	1,546	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Capital Stock	633	644	653	659	692	698	697	696	696	695	695	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Capital Surpluse	0	0	0	1,124,709	0	1,171,096	1,183,667	1,182,912	1,264,024	1,262,438	1,261,845	1,261,326	1,260,900	1,260,447	1,260,017	1,259,464	1,258,859	1,258,370	1,257,799	1,257,125	1,256,267	1,258,350	1,259,443	1,257,880	1,258,151	1,336,358	1,286,340	1,284,031	1,282,077	1,292,655	1,312,434	1,328,155	1,351,898	1,375,805	1,400,253	1,426,297	1,452,504	1,466,911	1,444,105	1,834,862	1,803,048	1,784,016	1,492,945	1,462,288	1,488,447	1,475,371	1,456,882	1,236,641	1,228,037	1,218,934	1,210,006	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cash	193,513	179,997	173,025	144,049	291,049	300,789	283,580	216,802	201,525	135,115	43,265	282,890	246,487	479,193	413,147	351,981	278,096	172,946	141,952	65,151	62,417	48,615	87,226	27,138	73,336	138,417	127,634	159,808	118,016	93,194	112,945	151,778	159,180	78,746	149,579	141,186	96,800	119,575	208,052	125,275	143,510	171,892	199,243	266,070	94,849	112,235	161,096	14,310	44,778	62,736	90,658	147,874	163,333	63,101	69,721	109,923	47,544	65,589	61,098	72,918	92,280	128,966	87,610	81,283	86,433	78,860	45,545	77,152	72,388	85,730	84,898	103,522	49,787	22,359	63,879	85,499	101,411	38,004	106,288	35,748	108,796
Cash And Equivalents	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cash And Short Term Investments	193,513	179,997	173,025	144,049	291,049	301,071	283,580	216,802	201,525	135,115	43,265	282,890	246,487	479,193	417,146	383,951	350,845	297,201	249,663	192,178	114,908	55,480	107,542	56,460	129,075	168,192	135,626	169,811	150,433	148,966	153,866	168,192	187,283	206,192	229,263	255,072	240,498	263,111	334,476	370,923	465,125	506,153	443,011	459,056	248,489	273,444	295,489	200,164	240,915	265,169	283,887	293,819	309,634	192,468	210,693	225,448	155,390	154,229	175,683	178,876	200,605	218,837	232,347	257,667	126,816	137,538	150,652	184,634	201,080	223,255	242,441	258,595	161,925	172,323	202,378	231,832	257,141	174,338	188,010	0	0
Common Stock	633	644	653	659	692	698	697	696	696	695	695	1,014	1,014	1,014	1,015	1,013	1,013	1,013	1,013	1,012	1,011	1,011	1,015	1,014	1,019	1,080	1,094	1,093	1,085	1,098	1,116	1,132	1,149	1,176	1,172	1,169	1,164	1,154	1,133	1,125	1,115	1,105	1,008	993	984	979	969	865	855	851	848	816	804	739	736	731	643	636	632	627	619	617	614	610	610	608	606	602	601	599	597	594	538	536	534	531	529	454	453	72	72
Common Stock Shares Outstanding	84,995	86,164	65,489	89,788	69,656	95,830	95,653	93,730	81,770	81,699	100,639	113,624	113,590	113,572	113,545	113,509	113,453	113,415	113,391	113,376	113,299	113,363	113,399	113,566	119,189	119,796	120,463	120,336	120,188	121,993	124,316	113,178	115,184	115,787	115,309	114,658	114,658	113,100	110,974	109,859	109,859	106,295	97,603	96,379	96,379	95,027	89,169	92,080	83,590	82,490	81,811	80,854	80,854	73,726	73,282	64,921	64,921	63,300	62,842	62,288	62,288	61,545	61,285	61,003	61,003	60,664	60,437	60,061	60,061	59,762	59,440	56,871	56,871	53,416	53,163	52,888	52,888	45,123	28,130	0	0
Common Stock Total Equity	0	0	0	659	0	698	697	696	696	695	695	1,014	1,014	1,014	1,015	1,013	1,013	1,013	1,013	1,012	1,011	1,011	1,015	1,014	1,019	1,080	1,094	1,093	1,085	1,098	1,116	1,132	1,149	1,176	1,172	1,169	1,164	1,154	1,133	1,125	1,115	1,105	1,008	993	984	979	969	865	855	851	848	816	804	739	736	731	643	636	632	627	619	617	614	610	610	608	606	602	601	599	597	594	538	536	534	531	529	454	453	0	0
Current Deferred Revenue	1,277	1,548	3,254	2,094	2,094	2,849	0	0	0	0	0	0	0	0	0	0	0	0	2,806	0	0	0	0	0	-19,681	885	885	885	885	885	885	885	885	885	885	885	1,082	1,082	1,082	8,814	9,289	9,601	8,974	9,881	4,593	4,945	5,771	5,771	18,697	20,887	20,553	21,238	21,922	22,802	22,802	22,801	23,722	22,061	22,026	21,223	23,788	23,996	23,996	22,589	22,519	22,740	21,221	21,221	19,273	22,032	21,452	17,480	16,994	12,021	12,021	11,563	10,959	10,959	10,279	0	0
Deferred Long Term Asset Charges	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	196,054	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Deferred Long Term Liab	0	0	0	5,392	97,607	101,062	104,518	107,974	111,430	114,885	118,341	121,797	125,253	128,708	132,164	135,620	139,076	142,531	145,987	149,443	152,899	156,354	159,810	163,266	166,722	1,551	1,772	1,993	2,214	2,435	2,656	2,878	3,099	3,420	3,644	3,852	3,893	4,112	4,342	10,138	10,229	9,806	10,451	10,544	11,088	11,065	11,890	13,521	127,838	130,163	132,911	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Earning Assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Good Will	17,905	17,905	14,882	27,946	26,713	15,995	5,544	1,844	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Intangible Assets	230,335	236,845	243,356	248,314	252,919	258,489	105,000	108,700	0	0	0	0	0	0	0	135,620	139,076	142,531	145,987	149,443	152,899	156,354	159,810	163,266	166,722	170,177	173,633	177,089	180,545	184,000	187,456	190,912	194,368	197,824	201,279	204,735	208,191	211,646	194,880	137,477	124,257	40,000	30,000	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Inventory	40,737	40,515	46,846	49,653	55,897	70,807	3,953	-93,515	-110,711	0	-104,262	0	-93,931	0	0	0	-79,427	0	-67,563	0	-83,286	0	0	-950	-754	-51,878	-61,796	-43,727	-46,847	-36,621	-35,817	-27,539	-26,228	-16,947	-13,997	-10,239	0	5,600	14,232	11,014	10,406	9,038	8,240	8,049	7,514	5,148	4,299	0	0	500	500	1,700	1,700	1,700	2,500	3,500	3,400	6,100	5,700	5,600	5,600	5,500	5,500	5,200	4,400	3,800	2,800	0	0	0	4,471	4,051	0	0	0	0	0	0	0	0	0
Liabilities And Stockholders Equity	1,243,507	1,188,104	1,118,241	1,129,768	1,231,497	1,121,700	1,137,639	1,107,474	926,395	887,239	789,150	1,088,290	999,570	922,256	879,619	788,011	724,826	675,953	642,307	590,114	548,193	277,693	338,692	276,745	367,337	390,972	372,023	391,872	378,996	370,542	378,109	387,829	424,072	437,631	462,086	488,699	521,654	553,713	605,610	605,034	681,255	666,016	594,704	591,519	368,582	383,943	399,422	217,727	258,782	283,325	303,120	315,108	331,202	212,580	232,449	249,930	181,393	183,472	206,085	214,792	236,156	255,262	281,390	299,515	161,983	198,623	208,008	247,659	262,424	292,350	318,897	327,334	224,835	196,988	233,801	259,196	286,022	204,974	219,001	0	0
Long Term Debt	446,234	445,718	445,201	444,692	540,373	443,679	443,178	538,747	394,653	392,295	389,989	387,728	385,517	383,350	381,230	379,152	377,120	388,644	386,675	384,744	382,855	381,002	486,527	484,591	574,362	578,449	638,712	702,325	708,341	719,449	722,287	734,513	748,271	744,085	738,472	732,063	725,636	705,109	737,500	287,500	287,500	287,500	459,960	460,000	172,500	172,500	172,500	172,500	172,500	172,500	172,500	172,513	172,569	172,609	172,675	172,713	172,775	172,811	172,859	172,786	172,819	172,849	172,879	172,908	435	462	488	513	538	570	589	607	631	1,114	1,337	1,593	1,779	2,150	2,392	4,398	7,867
Long Term Debt Total	0	0	0	444,692	0	443,679	443,178	442,731	0	392,295	389,989	387,728	385,517	383,350	381,230	379,152	377,120	388,644	386,675	384,744	382,855	381,002	486,527	484,591	574,362	578,449	638,712	702,325	708,341	719,449	722,287	734,513	748,271	744,085	738,472	732,063	725,636	705,109	737,500	287,500	287,500	287,500	459,960	460,000	172,500	172,500	172,500	172,500	172,500	172,500	172,500	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Long Term Investments	560,978	529,531	433,001	400,894	403,013	489,111	494,097	544,437	483,845	507,116	473,677	519,325	438,258	111,745	128,613	46,915	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3,932	42,856	47,752	34,349	59,831	55,374	88,333	90,314	99,342	95,194	88,962	83,208	140	240	340	340	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Negative Goodwill	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Debt	255,563	268,885	275,260	300,643	346,833	142,890	259,448	421,882	193,128	257,180	346,724	104,838	139,030	-95,843	-31,917	27,171	99,024	215,698	244,723	321,139	320,438	332,387	399,301	457,453	526,026	465,032	526,259	549,220	598,077	629,806	612,608	582,735	589,091	665,339	588,893	590,877	628,836	585,534	529,448	162,225	143,990	115,608	260,717	193,930	77,651	60,265	11,404	158,190	127,791	109,873	82,004	24,839	9,442	109,710	103,149	62,981	125,415	107,403	111,936	99,989	80,656	43,996	85,378	91,730	-85,897	-78,300	-44,963	-76,548	-71,763	-84,621	-83,636	-101,913	-47,912	-20,183	-61,385	-82,297	-97,011	-32,584	-100,094	0	0
Net Invested Capital	1,121,189	1,073,211	1,000,288	1,006,185	1,106,161	1,181,178	927,587	925,389	809,396	795,106	719,769	1,022,189	925,429	868,906	838,137	758,695	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Receivables	84,075	67,766	80,996	75,804	64,073	6,743	111,676	93,515	110,711	101,271	104,262	88,974	93,931	92,150	82,402	82,134	79,427	69,211	67,563	58,639	83,286	65,136	70,542	55,835	70,540	51,878	61,796	43,727	46,847	36,621	35,817	27,539	26,228	16,947	13,997	10,239	10,550	4,012	3,473	868	3,380	3,079	2,373	2,217	1,164	171	194	263	323	148	232	702	725	716	467	464	418	368	475	448	553	542	10,533	750	539	535	593	246	1,726	272	417	4,032	990	953	6,287	1,548	2,124	1,527	108	0	0
Net Tangible Assets	0	0	0	295,154	286,156	367,244	277,793	276,098	414,743	402,811	329,780	634,461	539,912	485,556	456,907	379,543	313,495	267,055	226,683	189,483	153,583	-111,357	-157,356	-213,558	-242,859	-222,961	-296,729	-334,186	-352,991	-367,864	-363,102	-361,969	-342,645	-322,999	-293,992	-260,143	-223,673	-404,782	-382,406	125,775	174,865	290,049	55,647	91,511	155,028	173,288	189,256	6,131	-87,052	-59,152	-37,482	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Working Capital	306,085	268,816	284,140	258,309	404,736	290,707	274,420	304,612	307,866	233,803	142,890	369,129	335,948	568,143	494,779	464,109	425,863	363,466	310,210	247,709	193,343	116,830	171,883	108,229	189,873	213,510	187,021	201,533	186,634	175,633	179,943	186,968	201,719	213,361	232,628	256,229	238,426	237,373	303,169	345,052	398,794	483,680	418,587	445,048	231,167	255,445	360,812	178,752	199,267	229,351	253,434	266,853	276,300	161,106	180,219	196,573	123,096	123,529	144,104	152,484	166,006	184,022	202,319	218,660	78,554	87,300	97,124	127,799	147,558	172,584	193,460	213,804	118,645	136,584	174,918	202,493	229,431	148,980	162,008	0	0
Non Current Assets Total	899,288	883,105	794,703	833,322	787,986	278,328	737,311	789,651	612,722	650,311	640,889	715,357	657,512	350,215	379,426	321,104	293,592	309,158	324,622	338,595	349,150	156,564	160,032	164,450	167,722	170,463	173,959	177,454	180,950	184,421	187,688	191,123	209,747	213,877	218,129	222,375	269,472	280,242	252,447	215,838	198,057	143,675	137,471	117,007	107,449	101,408	12,834	13,400	14,019	14,160	14,495	14,836	14,848	15,093	16,226	17,781	19,351	20,602	21,612	24,892	26,195	27,535	28,899	31,135	27,896	54,187	51,082	56,974	55,257	64,965	71,390	60,418	58,017	19,977	20,553	20,690	21,554	22,683	27,345	0	0
Non Current Liabilities Other	359	595	749	70,133	70,918	78,421	3,091	3,299	0	14	45	77	106	136	163	192	219	217	298	379	586	668	752	835	940	1,049	1,159	1,267	1,383	1,598	1,639	1,784	1,856	1,847	1,748	1,947	1,718	1,530	1,300	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non Current Liabilities Total	530,418	524,428	523,756	530,138	626,934	443,679	446,269	542,046	394,653	392,309	390,034	387,805	385,623	383,486	381,393	379,344	377,339	388,861	388,130	386,361	383,441	381,670	487,279	485,426	600,302	606,934	657,709	713,173	720,575	727,918	730,733	740,060	754,111	750,237	744,749	738,747	731,247	710,751	743,142	297,638	297,729	297,306	470,411	470,544	183,588	183,565	184,390	186,021	300,338	302,663	305,411	309,508	313,568	317,343	322,403	327,383	331,441	319,344	325,177	321,638	327,150	336,709	342,844	340,389	172,714	182,372	164,002	164,429	139,505	143,515	139,243	116,702	117,078	58,384	61,513	62,105	60,618	63,565	62,056	0	0
Non Currrent Assets Other	735,080	90,683	94,257	98,044	101,906	-489,111	105,675	108,287	108	136	162	188	214	239	264	288	139,388	142,579	146,024	149,480	152,936	156,391	159,847	164,253	167,513	170,214	173,670	177,126	180,582	184,040	187,514	190,930	209,526	213,629	217,853	218,140	226,292	20,780	23,218	8,796	8,188	6,779	8,205	8,655	3,101	2,867	-80,034	3,341	3,647	3,954	4,161	4,288	4,633	4,840	5,177	5,900	6,424	6,692	6,900	9,659	9,989	10,207	10,418	10,655	5,805	5,340	5,384	5,791	6,156	6,684	6,977	6,999	6,837	6,915	6,922	7,295	8,312	8,852	13,344	0	0
Noncontrolling Interest In Consolidated Entity	0	0	0	0	0	0	177,125	165,575	111,192	88,994	63,965	62,220	67,925	49,316	35,905	26,326	0	0	0	11,698	5,469	3,081	1,992	811	152	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Assets	757,998	0	0	0	198,471	677,506	222,423	209,308	425,211	143,180	167,193	196,008	657,484	238,437	250,776	274,147	293,259	309,134	177,151	337,026	348,990	156,391	159,847	163,303	166,759	170,214	173,670	177,126	180,582	184,040	187,514	190,930	209,526	213,629	217,853	226,004	269,148	280,178	252,447	206,104	187,819	135,112	128,519	107,997	98,295	91,829	86,382	3,341	3,647	3,954	4,161	4,288	4,633	4,840	5,177	5,900	6,424	6,692	6,900	9,659	9,989	10,207	10,418	11,655	7,805	34,340	32,384	40,791	40,156	50,684	57,977	46,999	44,837	6,915	6,922	7,295	8,312	8,852	13,344	18,386	20,624
Other Current Assets	25,894	16,721	22,671	26,940	32,492	-6,743	1,119	101,021	112,148	542	104,996	1,069	95,571	698	645	822	80,389	383	68,022	702	84,135	513	576	950	754	52,317	62,438	44,607	47,613	37,155	36,555	28,514	27,042	17,562	14,694	11,252	1,134	748	982	6,391	4,287	4,071	3,609	5,190	3,966	3,772	3,398	3,900	3,525	3,848	4,506	5,751	5,995	4,303	5,063	6,237	6,234	8,273	8,315	10,576	8,803	8,348	9,611	9,963	6,732	6,363	5,681	5,805	4,361	3,858	178	238	3,903	3,735	4,583	5,126	5,203	6,426	3,538	1,688	1,765
Other Current Liab	28,933	29,641	30,326	28,844	-63,767	-3,805	24,826	-85,235	5,780	3,036	5,341	3,790	6,044	3,275	5,219	2,676	5,361	3,294	3,213	3,358	5,689	4,190	6,719	4,000	3,822	-19,515	-5,300	2,993	2,647	5,524	6,190	3,176	4,695	4,003	3,254	3,774	12,674	34,443	47,113	29,784	67,532	23,327	24,838	16,058	19,996	17,388	15,016	14,483	20,917	15,119	12,311	9,767	15,798	11,601	11,258	10,585	13,248	16,053	16,345	14,081	16,773	17,069	22,999	22,327	25,956	28,344	30,595	32,756	24,238	24,155	21,429	23,201	21,817	19,563	16,953	12,959	15,532	15,273	13,005	13,492	9,341
Other Liab	0	0	76,697	0	84,185	78,781	0	0	0	0	0	0	106	0	163	192	0	217	298	379	586	668	752	835	940	2,600	2,931	3,260	3,597	4,033	4,295	4,662	4,955	5,267	5,392	5,799	5,611	5,642	5,642	10,138	10,229	9,806	10,451	10,544	11,088	11,065	11,890	13,521	127,838	130,163	132,911	136,995	140,999	144,734	149,728	154,670	158,666	146,533	152,318	148,852	154,331	163,860	169,965	167,481	172,279	181,910	163,514	163,916	138,967	142,945	138,654	116,095	116,447	57,270	60,176	60,512	58,839	61,415	59,664	33,096	10,320
Other Stockholder Equity	699,511	713,569	723,200	730,880	770,007	136,675	789,838	789,083	870,195	868,609	868,016	1,261,326	1,260,900	1,260,447	1,260,017	1,259,464	1,258,859	1,258,370	1,257,799	1,257,125	1,256,267	1,255,087	1,256,180	1,254,617	1,254,888	1,333,095	1,283,077	1,280,768	1,278,814	1,289,392	1,309,171	1,324,892	1,348,635	1,372,542	1,396,990	1,423,034	1,449,241	1,463,648	1,444,105	1,834,862	1,803,048	1,784,016	1,492,945	1,462,288	1,488,447	1,475,371	1,456,882	1,236,641	1,228,037	1,218,934	1,210,006	1,194,620	1,177,359	1,039,357	1,033,427	1,025,548	927,082	918,634	912,070	905,453	895,383	889,844	882,369	876,007	870,878	863,177	855,951	846,924	840,498	833,452	827,704	818,160	676,299	674,109	673,969	671,144	669,698	357,381	558,839	0	0
Preferred Stock Redeemable	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Total Equity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	367,358	367,358
Property Plant And Equipment Gross	3,019	3,189	2,880	3,153	3,435	3,844	0	0	12	0	19	24	28	33	37	42	33	24	1,484	1,569	160	173	185	197	209	249	289	328	368	381	174	193	221	248	276	303	324	64	0	9,734	10,238	8,563	8,952	9,010	9,154	9,579	9,660	10,059	10,372	10,206	10,334	10,548	10,215	10,253	11,049	11,881	12,927	13,910	14,712	15,233	16,206	17,328	18,481	19,480	20,091	19,847	18,698	16,183	15,101	14,281	13,413	13,419	13,180	13,062	13,631	13,395	13,242	13,831	14,001	0	0
Property Plant And Equipment Net	3,019	3,189	2,880	3,153	3,435	3,844	3,721	3,985	12	15	19	24	28	33	37	42	33	24	1,484	1,569	160	173	185	197	209	249	289	328	368	381	174	193	221	248	276	303	324	64	0	9,734	10,238	8,563	8,952	9,010	9,154	9,579	9,660	10,059	10,372	10,206	10,334	10,548	10,215	10,253	11,049	11,881	12,927	13,910	14,712	15,233	16,206	17,328	18,481	19,480	20,091	19,847	18,698	16,183	15,101	14,281	13,413	13,419	13,180	13,062	13,631	13,395	13,242	13,831	14,001	0	0
Property Plant Equipment	0	0	0	180	3,435	165	176	3,985	12	15	19	24	28	33	37	42	333	24	1,484	148	160	173	185	197	209	249	289	328	368	381	174	193	221	248	276	303	324	64	0	9,734	10,238	8,563	8,952	9,010	9,154	9,579	9,660	10,059	10,372	10,206	10,334	10,548	10,215	10,253	11,049	11,881	12,927	13,910	14,712	15,233	16,206	17,328	18,481	19,480	20,091	19,847	18,698	16,183	15,101	14,281	13,413	13,419	13,180	13,062	13,631	13,395	13,242	13,831	14,001	15,815	20,267
Retained Earnings	-25,189	-86,720	-168,766	-170,046	-204,911	-136,675	-402,198	-403,137	-456,148	-466,493	-538,931	-627,879	-722,002	-775,905	-804,123	-880,967	-946,404	-992,353	-1,032,162	-1,069,902	-1,103,692	-1,367,452	-1,414,541	-1,469,167	-1,498,748	-1,557,133	-1,580,900	-1,616,046	-1,632,891	-1,658,362	-1,673,395	-1,687,992	-1,692,427	-1,696,728	-1,692,144	-1,684,334	-1,673,667	-1,657,741	-1,636,470	-1,572,906	-1,505,203	-1,455,274	-1,408,291	-1,371,862	-1,334,502	-1,303,178	-1,268,486	-1,231,366	-1,315,960	-1,278,953	-1,248,328	-1,223,283	-1,200,616	-1,181,317	-1,160,095	-1,139,290	-1,116,754	-1,094,544	-1,072,361	-1,050,669	-1,031,452	-1,015,527	-994,599	-967,573	-937,809	-904,751	-872,387	-827,262	-777,812	-739,975	-702,195	-660,720	-611,768	-569,557	-531,771	-500,055	-468,604	-439,433	-417,145	0	0
Retained Earnings Total Equity	0	0	0	-170,046	0	-136,597	-402,198	-403,137	-456,148	-466,493	-538,931	-627,879	-722,002	-775,905	-804,123	-880,967	0	0	0	-1,069,902	-1,103,692	-1,367,452	-1,414,541	-1,469,167	-1,498,748	-1,557,133	-1,580,900	-1,616,046	-1,632,891	-1,658,362	-1,673,395	-1,687,992	-1,692,427	-1,696,728	-1,692,144	-1,684,334	-1,673,667	-1,657,741	-1,636,470	-1,572,906	-1,505,203	-1,455,274	-1,408,291	-1,371,862	-1,334,502	-1,303,178	-1,268,486	-1,231,366	-1,315,960	-1,278,953	-1,248,328	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Short Long Term Debt	0	0	0	0	96,193	96,131	96,072	96,016	0	0	0	0	0	0	0	0	0	0	317	308	0	0	486,527	484,591	25,000	25,000	653,893	709,028	7,752	3,551	3,266	3,266	733,131	0	0	0	725,636	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Short Long Term Debt Total	449,076	448,882	448,285	444,692	637,882	443,679	543,028	638,684	394,653	392,295	389,989	387,728	385,517	383,350	381,230	379,152	377,120	388,644	386,675	386,290	382,855	381,002	486,527	484,591	599,362	603,449	653,893	709,028	716,093	723,000	725,553	734,513	748,271	744,085	738,472	732,063	725,636	705,109	737,500	287,500	287,500	287,500	459,960	460,000	172,500	172,500	172,500	172,500	172,569	172,609	172,662	172,713	172,775	172,811	172,870	172,904	172,959	172,992	173,034	172,907	172,936	172,962	172,988	173,013	536	560	582	604	625	1,109	1,262	1,609	1,875	2,176	2,494	3,202	4,400	5,420	6,194	0	0
Short Term Debt	1,207	1,211	1,226	1,266	97,509	96,131	96,759	96,638	0	0	0	0	25,000	0	0	0	0	0	317	308	0	0	486,527	484,591	25,000	25,000	15,181	6,703	7,752	3,551	3,266	5,101	6,208	5,351	6,728	4,411	725,636	0	0	0	0	0	0	0	0	0	0	13	69	109	162	200	206	202	195	191	184	181	175	121	117	113	109	105	101	98	94	91	87	539	673	1,002	1,244	1,062	1,157	1,609	2,621	3,270	3,802	0	0
Short Term Investments	0	-422,491	-397,940	-400,894	403,013	282	0	544,437	483,845	507,116	473,677	519,325	438,258	111,745	3,999	31,970	72,749	124,255	107,711	127,027	52,491	6,865	20,316	29,322	55,739	29,775	7,992	10,003	32,417	55,772	40,921	16,414	28,103	127,446	79,684	109,954	143,698	143,536	126,424	245,648	321,615	334,261	243,768	192,986	153,640	161,209	134,393	185,854	196,137	202,433	193,229	145,945	146,301	129,367	140,972	115,525	107,846	88,640	114,585	105,958	108,325	89,871	144,737	176,384	40,383	58,678	105,107	107,482	128,692	137,525	157,543	155,073	112,138	149,964	138,499	146,333	155,730	136,334	81,722	53,404	39,754
Temporary Equity Redeemable Noncontrolling Interests	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total Assets	1,243,507	1,188,104	1,118,241	1,129,768	1,231,497	1,327,712	1,137,639	1,107,474	926,395	887,239	789,150	1,088,290	999,570	922,256	879,619	788,011	724,826	675,953	642,307	590,114	548,193	277,693	338,692	276,745	367,337	390,972	372,023	391,872	378,996	370,542	378,109	387,829	424,072	437,631	462,086	488,699	521,654	553,713	605,610	605,034	681,255	666,016	594,704	591,519	368,582	383,943	399,422	217,727	258,782	283,325	303,120	315,108	331,202	212,580	232,449	249,930	181,393	183,472	206,085	214,792	236,156	255,262	281,390	299,515	161,983	198,623	208,008	247,659	262,424	292,350	318,897	327,334	224,835	196,988	233,801	259,196	286,022	204,974	219,001	125,449	192,715
Total Current Assets	344,219	304,999	323,538	296,446	443,511	371,878	400,328	317,823	313,673	236,928	148,261	372,933	342,058	572,041	500,193	466,907	431,234	366,795	317,685	251,519	199,043	121,129	178,660	112,295	199,615	220,509	198,064	214,418	198,046	186,121	190,421	196,706	214,325	223,754	243,957	266,324	252,182	273,471	353,163	389,196	483,198	522,341	457,233	474,512	261,133	282,535	386,588	204,327	244,763	269,165	288,625	300,272	316,354	197,487	216,223	232,149	162,042	162,870	184,473	189,900	209,961	227,727	252,491	268,380	134,087	144,436	156,926	190,685	207,167	227,385	247,507	266,916	166,818	177,011	213,248	238,506	264,468	182,291	191,656	0	0
Total Current Liabilities	38,134	36,183	39,398	38,137	38,775	36,653	125,908	13,211	5,807	3,125	5,371	3,804	6,110	3,898	5,414	2,798	5,371	3,329	7,475	3,810	5,700	4,299	6,777	4,066	9,742	6,999	11,043	12,885	11,412	10,488	10,478	9,738	12,606	10,393	11,329	10,095	13,756	36,098	49,994	44,144	84,404	38,661	38,646	29,464	29,966	27,090	25,776	25,575	45,496	39,814	35,191	33,419	40,054	36,381	36,004	35,576	38,946	39,341	40,369	37,416	43,955	43,705	50,172	49,720	55,533	57,136	59,802	62,886	59,609	54,801	54,047	53,112	48,173	40,427	38,330	36,013	35,037	33,311	29,648	20,163	39,104
Total Liab	568,552	560,611	563,154	568,275	665,709	686,344	572,177	555,257	400,460	395,434	395,405	391,609	391,733	387,384	386,807	382,142	382,710	392,190	395,605	390,171	389,141	385,969	494,056	489,492	610,044	613,933	668,752	726,058	731,987	738,406	741,211	749,798	766,717	760,630	756,078	748,842	745,003	746,849	793,136	341,782	382,133	335,967	509,057	500,008	213,554	210,655	210,166	211,596	345,834	342,477	340,602	342,927	353,622	353,724	358,407	362,959	370,387	358,685	365,546	359,054	371,105	380,414	393,016	390,109	228,247	239,508	223,804	227,315	199,114	198,316	193,290	169,814	165,251	98,811	99,843	98,118	95,655	96,876	91,704	57,657	57,291
Total Permanent Equity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total Stockholder Equity	674,955	627,493	555,087	561,493	565,788	641,368	388,337	386,642	414,743	402,811	329,780	634,461	539,912	485,556	456,907	379,543	313,495	267,055	226,683	188,245	153,583	-111,357	-157,356	-213,558	-242,859	-222,961	-296,729	-334,186	-352,991	-367,864	-363,102	-361,969	-342,645	-322,999	-293,992	-260,143	-223,349	-193,136	-187,526	263,252	299,122	330,049	85,647	91,511	155,028	173,288	189,256	6,131	-87,052	-59,152	-37,482	-27,819	-22,420	-141,144	-125,958	-113,029	-188,994	-175,213	-159,461	-144,262	-134,949	-125,152	-111,626	-90,594	-66,264	-40,885	-15,796	20,344	63,310	94,034	125,607	157,520	59,584	98,177	133,958	161,078	190,367	108,098	127,297	67,792	135,424
Treasury Stock	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-3,263	-3,263	-3,263	-3,263	-3,263	-3,263	-3,263	-3,263	-3,263	-3,263	-3,263	-3,263	-3,263	-3,263	-3,263	-3,263	-3,263	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Warrants	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Cash Flow

Currency in USD. All numbers in thousands.

	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31	2005-12-31	2004-12-31	2003-12-31	2002-12-31
Begin Period Cash Flow	291,049	201,525	246,487	278,096	62,417	73,336	118,016	159,180	96,800	143,510	94,849	44,778	163,333	47,544	92,280	86,433	72,388	49,787	101,411	35,748	108,796	49,114
Capital Expenditures	411	67	1,304	13	12	12	12	278	7	689	87,734	2,590	3,628	861	744	1,031	9,818	5,708	3,443	2,085	763	6,986
Cash And Cash Equivalents Changes	0	0	-44,962	-31,609	0	-10,919	-44,680	-41,164	62,380	-46,710	48,661	50,071	-118,555	0	0	0	0	0	0	0	0	0
Cash Flows Other Operating	0	0	203	-813	0	-420	-313	59,375	-18,440	-163,226	-171,542	-20,171	-110,627	0	0	0	0	0	0	0	0	0
Change In Cash	-97,536	89,524	-44,962	-31,609	215,679	-10,919	-44,680	-41,164	62,380	-46,710	48,661	50,071	-118,555	115,789	-44,736	5,847	14,045	22,601	-51,624	65,663	-73,048	59,682
Change In Working Capital	-24,791	6,866	-16,873	-14,322	3,095	-16,760	-28,280	-21,964	-16,853	-30,251	5,770	-140,708	-5,509	-16,668	1,710	-31,326	28,540	34,463	74,207	37,416	29,639	9,012
Change Receivables	0	0	-16,780	-14,504	0	-12,746	-23,693	-20,619	-15,678	-7,297	-1,415	-841	-29	0	0	0	0	0	0	0	0	0
Change To Account Receivables	-20,002	9,794	-16,780	-14,504	3,859	-12,746	-23,693	-20,619	-15,678	-7,297	-1,415	-841	0	-448	0	0	0	0	0	0	0	0
Change To Inventory	-12,004	280	280	280	-664	-3,428	-1,961	230	-1,108	-1,908	-3,100	-4,822	0	4,499	0	0	0	0	0	0	0	0
Change To Liabilities	0	-663	-39	860	-1	-3,919	-2,626	-1,575	-1,495	-22,532	11,126	-133,416	-10,197	3,085	0	0	0	9,478	9,189	6,681	1,748	939
Change To Netincome	0	-40,628	91,864	11,862	75,402	-187,076	16,788	6,611	28,868	47,915	27,126	23,970	24,932	0	0	0	0	0	0	0	0	0
Change To Operating Activities	0	-12,571	-54	126	-763	-3,424	-1,961	230	-1,108	-10,170	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	35,705	19,512	13,832	13,840	13,874	13,872	13,982	13,954	13,933	12,175	8,203	7,326	7,583	6,336	5,541	6,962	4,058	4,198	4,107	4,812	5,209	5,124
Dividends Paid	-96,281	0	0	0	11	80	281	960	87,331	56,988	0	0	0	0	0	0	0	0	0	0	0	0
End Period Cash Flow	193,513	291,049	201,525	246,487	278,096	62,417	73,336	118,016	159,180	96,800	143,510	94,849	44,778	163,333	47,544	92,280	86,433	72,388	49,787	101,411	35,748	108,796
Exchange Rate Changes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Free Cash Flow	140,653	201,659	362,509	313,100	257,446	223,531	141,748	60,706	10,124	-131,412	-217,336	-130,544	-91,966	-76,005	-58,808	-100,942	-114,190	-110,499	-62,088	-49,908	-32,439	-65,587
Investments	-70,288	-56,634	43,722	-314,924	-17,991	3,519	-23,236	-4,580	159,175	69,656	-131,846	-55,753	-52,191	0	0	0	0	0	0	0	0	0
Issuance Of Capital Stock	139	370	1,169	436	627	1,139	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Borrowings	0	87,405	87,405	87,405	-13,750	-230,000	-50,939	-18,398	-18,398	434,677	244,822	-69	-206	0	0	0	0	0	0	0	0	0
Net Income	179,722	220,262	368,837	293,814	190,993	406,328	134,272	59,536	-18,760	-168,464	-170,701	-18,542	-115,344	-83,862	-85,302	-93,643	-159,997	-166,044	-143,164	-102,654	-70,583	-79,227
Other Cashflows From Financing Activities	96,281	117,778	-59,457	-30,129	-10,553	-5,955	429,721	578	159,168	157,136	244,822	-58,283	-55,819	-40,312	1,736	166,631	-88	-18,582	-2,525	-3,470	-28,181	26,591
Other Cashflows From Investing Activities	0	0	-67,120	0	-17,991	3,519	-23,236	-4,302	159,175	-134,167	-85,000	60	575	557	2,875	0	50	0	677	4,746	1,004	0
Other Non Cash Items	-59,809	-77,267	-80,432	-42,337	5,565	12,912	11,941	1,161	24,938	28,427	1,439	187	16	41	-13	18,096	23,027	22,592	6,205	12,603	4,059	6,490
Sale Purchase Of Stock	-75,805	-8,585	-394,209	-92	-89	-3,073	-99,628	-79,173	-25,636	48,925	153,021	236,377	25,808	0	0	0	0	0	0	-3	0	0
Stock Based Compensation	5,837	7,347	2,017	1,698	2,056	3,233	9,833	8,297	6,873	27,390	25,687	23,783	24,916	19,009	20,000	18,019	22,494	21,831	5,623	8,521	0	0
Total Cash From Financing Activities	-171,839	-55,568	-452,497	-29,785	-23,776	-237,969	-163,192	-97,568	-106,919	149,073	397,843	236,308	25,602	231,245	11,592	173,124	7,825	145,974	3,682	213,854	-27,763	66,707
Total Cash From Operating Activities	141,064	201,726	363,813	313,113	257,458	223,531	141,748	60,984	10,131	-130,723	-129,602	-127,954	-88,338	-75,144	-58,064	-99,911	-104,372	-104,791	-58,645	-47,823	-31,676	-58,601
Total Cashflows From Investing Activities	0	-56,634	43,722	-314,937	-18,003	3,519	-23,236	-4,580	159,168	-65,060	-219,580	-58,283	-55,819	0	1,736	0	110,592	0	3,339	0	0	51,576

	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30	2004-06-30	2003-12-31	2002-12-31
Begin Period Cash Flow	179,997	173,025	144,049	291,049	300,829	283,580	216,802	201,525	135,115	43,265	282,890	246,487	479,193	413,147	351,981	278,096	172,946	141,952	65,151	62,417	48,615	87,226	27,138	73,336	138,417	127,634	159,808	118,016	93,194	112,945	151,778	159,180	78,746	149,579	141,186	96,800	119,575	208,052	125,275	143,510	171,892	199,243	266,070	94,849	112,235	161,096	14,310	44,778	62,736	90,658	147,874	163,333	63,101	69,721	109,923	47,544	65,589	61,098	72,918	92,280	128,966	87,610	81,283	86,433	78,860	45,545	77,152	72,388	85,730	84,898	103,522	49,787	22,359	63,879	85,499	101,411	38,004	106,288	0	0	0
Capital Expenditures	151	227	0	33	34	11	13	9	22,282	9	9	-4	13	13	-5	13	12	12	12	12	-13	-12	-12	-12	-40	-40	-39	-40	28	242	8	-28	1	6	6	6	133	25,000	43,936	56,620	46,067	10,236	30,691	740	261	567	659	1,103	905	40	1,382	1,381	575	153	133	-1,046	117	268	357	2	68	172	576	1,367	2,253	2,804	3,195	1,566	1,551	2,172	1,521	464	804	1,012	896	731	684	784	617	763	6,986
Cash And Cash Equivalents Changes	0	0	0	-147,000	0	17,249	66,778	15,277	66,410	91,850	-239,625	36,403	-232,706	66,046	61,166	73,885	0	0	0	2,734	13,802	-38,611	60,088	-46,198	-65,081	10,783	-32,174	41,792	24,822	-19,751	-38,833	-7,402	80,434	-70,833	8,393	44,386	-22,775	-88,477	82,777	-18,235	-28,382	-27,351	-66,827	171,221	-17,386	-48,861	146,786	-30,468	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cash Flows Other Operating	0	0	0	16,961	0	-2,464	1,590	1,444	-895	192	335	571	-1,212	217	123	59	0	0	0	-6	-418	-18	293	-277	-397	-51,869	35,303	16,650	26,912	15,175	17,449	-161	4,107	-4,504	-7,481	-10,562	-11,421	-20,133	-60,955	-70,717	-50,319	-47,415	-35,022	-38,786	-32,160	-35,268	47,775	-518	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change In Cash	13,516	6,972	28,976	-147,000	-9,780	17,249	66,778	15,277	66,410	91,850	-239,625	36,403	-232,706	66,046	61,166	73,885	105,150	30,994	76,801	2,734	13,802	-38,611	60,088	-46,198	-65,081	10,783	-32,174	41,792	24,822	-19,751	-38,833	-7,402	80,434	-70,833	8,393	44,386	-22,775	-88,477	82,777	-18,235	-28,382	-27,351	-66,827	171,221	-17,386	-48,861	146,786	-30,468	-17,958	-27,922	-57,216	-15,459	100,232	-6,620	-40,202	62,379	-18,045	4,491	-11,820	-19,362	-36,686	41,356	6,327	-5,150	7,573	33,315	-31,607	4,764	-13,342	832	-18,624	53,735	27,428	-41,520	-21,620	-15,912	63,407	-68,284	0	0	0
Change In Working Capital	-29,775	17,333	-4,930	-7,419	-23,474	18,273	-6,132	18,199	-7,637	934	-13,389	3,219	-244	-11,590	2,577	-5,065	-8,949	-5,394	-5,094	22,532	-17,077	3,024	-11,606	8,899	-18,559	5,870	-19,881	4,290	-9,792	-702	-7,559	-3,911	-7,391	-4,227	-2,652	-2,583	-18,856	-8,739	-2,789	133	1,453	-2,589	10,591	-3,685	-1,167	-587	-4,887	-134,067	3,317	1,654	-64	-10,416	-2,127	-4,034	-3,389	-7,118	13,691	-6,685	8,608	-13,904	-9,739	-1,436	-9,052	-11,099	-10,771	16,252	-3,793	26,852	-50	6,444	27,088	981	66,314	5,808	-1,722	3,807	531	2,881	0	0	0
Change Receivables	0	0	0	-11,731	0	2,483	-18,161	17,196	-9,440	2,991	-15,288	4,957	-1,781	-9,748	-268	-2,707	0	0	0	24,647	-18,150	5,406	-14,707	14,705	-18,662	9,918	-18,069	3,120	-10,226	-804	-8,278	-1,311	-9,281	-2,950	-3,758	311	-6,538	-539	-2,358	2,138	1,109	-3,895	2,698	-1,327	-993	23	-31	160	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Account Receivables	-16,310	13,231	-5,192	-11,731	8,276	2,483	-18,161	17,196	-9,440	2,991	-15,288	4,957	-1,781	-9,748	-268	-2,707	-10,216	-1,648	-8,924	24,647	-18,150	5,406	-14,707	14,705	-18,662	9,918	-18,069	3,120	-10,226	-804	-8,278	-1,311	-9,281	-2,950	-3,758	311	-6,538	-539	-2,358	2,138	10	-256	-16	-1,153	445	1,703	129	160	0	113	0	268	-448	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Inventory	-8,207	902	-4,101	-598	-70	350	350	350	350	0	0	0	0	0	0	0	1,254	0	0	0	0	0	3,107	-5,273	2,567	-4,179	436	-785	1,055	-68	1,380	-2,137	1,441	-745	1,877	-3,681	1,908	-6,680	-1,478	-430	-188	-379	-52	-2,481	-255	-268	-4,299	-7,032	0	0	0	-5,958	4,188	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Liabilities	0	0	-181	-1,048	-1,621	21,129	10,439	-441	-62	59	16	-2,309	2,479	-1,789	2,668	-2,498	-25	-1,104	995	-2,190	1,409	-2,445	2,727	-5,610	418	-4,251	-2,050	1,284	663	-120	522	-2,439	2,084	-1,357	777	-2,999	-13,071	-9,338	-1,562	1,439	922	2,117	6,507	1,549	917	234	-858	-133,709	8,436	0	0	0	3,085	0	0	0	0	0	0	0	0	0	0	0	0	0	0	145	9,478	2,261	1,697	3,938	9,189	5,807	3,108	1,058	6,681	3,202	2,625	1,748	939
Change To Netincome	0	0	32,890	-17,093	93,118	-241,130	59,651	38,167	89,859	17,575	3,336	-34,478	5,153	38,683	-26,426	-5,548	24,421	17,698	18,378	9,113	-195,568	1,734	1,452	5,306	2,427	8,898	3,257	2,507	-467	1,716	3,014	2,547	5,819	7,081	8,231	7,154	21,904	4,732	7,746	13,533	5,983	6,467	7,160	7,516	5,934	5,824	5,977	6,235	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Operating Activities	0	0	4,494	4,494	-6,281	-10,319	9,514	805	1,865	-2,116	1,883	-1,686	2,094	-2,270	2,772	-2,470	1,292	-2,642	2,835	-2,248	1,171	-2,433	3,109	-5,271	-1,961	-4,179	436	-785	230	222	197	-161	-1,108	0	0	0	-10,170	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	9,994	9,994	8,433	7,284	7,005	5,415	3,591	3,501	3,456	3,458	3,458	3,460	3,458	3,461	3,458	3,463	3,474	3,320	3,541	3,539	3,468	3,468	3,468	3,468	3,495	3,496	3,495	3,496	3,496	3,491	3,484	3,483	3,484	3,483	3,483	3,483	3,455	2,530	2,790	3,400	2,519	1,794	1,992	1,898	1,864	1,890	1,662	1,910	2,124	2,052	1,757	1,650	1,639	1,560	1,622	1,515	1,515	1,497	1,324	1,205	1,218	1,588	2,318	1,838	1,533	834	820	871	1,110	1,047	1,061	980	1,015	1,035	971	1,086	1,186	1,195	0	0	0
Dividends Paid	-77	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	13,839	0	3	8	8	17	17	38	135	39	40	67	65	52	124	719	187	29,099	29,251	28,794	28,650	28,338	277,541	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
End Period Cash Flow	193,513	179,997	173,025	144,049	291,049	300,829	283,580	216,802	201,525	135,115	43,265	282,890	246,487	479,193	413,147	351,981	278,096	172,946	141,952	65,151	62,417	48,615	87,226	27,138	73,336	138,417	127,634	159,808	118,016	93,194	112,945	151,778	159,180	78,746	149,579	141,186	96,800	119,575	208,052	125,275	143,510	171,892	199,243	266,070	94,849	112,235	161,096	14,310	44,778	62,736	90,658	147,874	163,333	63,101	69,721	109,923	47,544	65,589	61,098	72,918	92,280	128,966	87,610	81,283	86,433	78,860	45,545	77,152	72,388	85,730	84,898	103,522	49,787	22,359	63,879	85,499	101,411	38,004	106,288	0	0
Exchange Rate Changes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Free Cash Flow	33,105	43,715	38,182	25,651	8,865	15,679	79,022	98,093	76,099	96,711	84,614	84,107	85,280	74,558	79,794	73,468	66,893	57,402	56,496	76,655	61,777	60,115	51,725	49,914	47,858	43,490	22,639	27,761	21,058	19,946	12,452	7,250	6,916	2,656	2,174	-1,622	-4,743	-46,071	-98,341	-107,257	-86,041	-51,547	-47,377	-32,371	-24,954	-28,132	-35,027	-42,431	-26,261	-19,292	-19,141	-27,272	-15,646	-19,339	-17,381	-23,639	-2,499	-22,638	-6,840	-26,831	-19,871	-16,144	-27,756	-37,171	-38,121	-12,566	-45,740	-17,763	-32,738	-27,764	-7,583	-42,414	26,128	-30,663	-32,123	-25,430	-25,508	-17,085	0	0	0
Investments	-5,151	-25,888	0	-35,689	-8,678	1	-2,509	-143,156	-19,905	-19,905	90,021	-26,394	-315,481	-8,500	-7,000	16,057	51,994	-15,937	20,107	-74,167	-45,594	13,522	9,078	26,513	-25,880	-21,774	2,023	22,395	23,348	-14,853	-24,490	11,693	99,289	-47,875	34,045	73,716	889	-34,545	32,702	70,750	44,641	-89,373	-42,842	-44,272	407	-33,145	-32,502	9,487	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Issuance Of Capital Stock	59	0	111	0	28	1	81	260	1,046	63	60	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Borrowings	0	0	0	-96,204	0	-87,405	-256	87,661	87,661	87,661	87,661	0	0	0	0	0	-13,750	-13,750	-13,750	-13,750	0	-110,000	-110,000	-120,000	-50,939	429,697	-56,679	-7,752	-18,398	-3,475	-3,475	-3,475	-18,398	0	0	0	5,600	8,634	420,443	0	0	-1	-50	244,873	0	0	-13	-56	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Income	61,531	82,046	1,280	34,865	-68,314	229,347	21,371	37,858	45,650	102,646	110,846	109,695	75,016	41,621	98,225	78,952	57,862	47,051	46,061	40,019	269,215	50,167	56,616	30,330	58,514	23,767	35,146	16,845	25,471	15,033	14,597	4,435	4,301	-4,584	-7,810	-10,667	-15,926	-21,271	-63,564	-67,703	-49,929	-46,983	-36,429	-37,360	-31,324	-34,692	-37,120	84,594	-37,007	-30,625	-25,045	-22,667	-19,299	-21,222	-20,805	-22,536	-22,210	-22,183	-21,692	-19,217	-15,925	-20,928	-27,026	-29,764	-33,058	-32,364	-45,125	-49,450	-37,837	-37,780	-41,475	-48,952	-42,211	-37,786	-31,716	-31,451	-29,171	-22,288	0	0	0
Other Cashflows From Financing Activities	96,281	-11,082	-9,206	-136,962	-1,515	-96,152	-9,803	225,248	-13,099	-4,912	-20,161	-21,285	-2,511	-8,500	-11,808	-15,810	13,839	-10,553	20,107	65	226,933	-1,989	-809	-90	24	429,697	2,023	22,395	187	-15,095	-7,704	442	-25,636	-47,875	34,045	73,710	5,600	-19,704	142,902	14,130	-1,426	-1	-50	244,873	-229,147	12,416	214,268	8,384	2,891	1,360	9,824	-1,239	-18,034	11,189	-25,483	-7,984	-19,469	25,331	-6,658	2,532	-27	-27	-24	166,709	-23	-22	-22	-21	-484	-153	-347	-266	-301	-318	-708	-1,198	-1,020	-949	0	0	0
Other Cashflows From Investing Activities	0	0	0	0	0	97,732	-47,956	-86,930	-177,120	0	110,000	0	0	0	0	16,057	-17,991	-69,997	-54,060	-74,167	3,519	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-9,167	-25,000	-45,000	-55,000	-45,000	-10,000	-30,000	100	160	160	60	0	575	490	390	300	557	557	527	10	2,875	2,739	2,738	238	0	0	0	0	50	50	30	30	0	0	0	0	677	677	1,031	756	4,746	4,397	914	1,004	0
Other Non Cash Items	-15,286	-65,225	30,534	-9,832	96,608	-264,336	59,731	30,730	45,526	-31,400	-42,104	-52,454	-9,128	31,759	-44,732	-20,236	1,654	1,377	1,082	1,452	1,771	1,786	1,855	2,011	2,081	1,471	633	606	627	644	859	1,382	4,832	6,382	7,172	7,189	21,385	1,550	1,412	-2	-1,441	22	-2	1,421	195	-6	-2	0	-105	15	0	1	-10	14	1	3	5	5	3	-26	4,643	4,804	5,428	3,221	5,866	5,516	5,746	5,530	5,590	4,697	7,292	5,013	1,814	1,292	1,240	1,859	2,630	1,911	0	0	0
Sale Purchase Of Stock	-14,648	-11,082	-9,317	-40,758	-8,514	-12	-13	-46	-13	-12	-394,159	-25	-9	-11	-17	-55	-8	-7	-9	-65	9	-242	-229	-2,611	-80,945	-17,836	-294	-553	-12,724	-21,521	-19,129	-25,799	-25,584	3,485	1,425	1,086	13,296	11,843	5,514	18,272	13,018	113,570	23,442	2,991	7,161	12,416	214,268	2,532	25,808	22,917	21,557	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Stock Based Compensation	1,277	1,442	1,520	1,598	1,326	3,717	1,350	954	554	542	470	451	447	441	375	435	488	489	474	605	486	-874	1,452	2,169	2,427	2,472	2,427	2,507	1,874	1,718	2,841	1,864	1,650	1,468	1,822	1,933	1,377	4,732	7,746	13,535	5,983	6,447	7,162	6,095	5,739	5,830	5,979	6,235	6,210	7,572	5,593	5,541	4,693	4,496	5,323	4,497	4,617	4,996	5,274	5,113	18,019	0	0	4,914	22,494	0	3	5,788	21,831	3	3	5,013	5,623	0	0	1,408	0	0	0	0	0
Total Cash From Financing Activities	-14,589	-11,082	-9,206	-136,962	-10,001	-96,163	-9,735	60,331	-12,066	-4,861	-414,260	-21,310	-2,505	-12	-11,628	-15,640	-13,749	-10,471	198	246	-2,381	-112,248	-715	-122,625	-87,059	-10,933	-56,836	-8,364	-19,584	-24,844	-26,795	-26,345	-25,771	-25,614	-27,826	-27,708	-9,754	-7,861	148,416	18,272	13,018	113,569	23,392	247,864	7,161	12,416	214,255	2,476	2,851	1,307	9,773	11,671	133,337	1,377	2,529	94,002	3,806	1,530	1,321	4,935	896	2,698	2,607	166,923	2,350	1,332	3,540	603	1,175	839	2,403	141,557	1,361	737	2,067	-483	108,440	-113	105,527	0	66,707
Total Cash From Operating Activities	33,256	43,942	38,182	25,684	8,899	15,690	79,035	98,102	98,381	96,711	84,614	84,107	85,280	74,558	79,794	73,481	66,905	57,402	56,496	76,655	61,777	60,115	51,725	49,914	47,858	43,490	22,639	27,761	21,086	20,188	12,460	7,250	6,917	2,656	2,174	-1,616	-4,610	-21,071	-54,405	-50,637	-39,974	-41,311	-16,686	-31,631	-24,693	-27,565	-34,368	-41,328	-25,356	-19,332	-17,759	-25,891	-15,071	-19,186	-17,248	-23,639	-2,382	-22,370	-6,483	-26,829	-19,803	-15,972	-28,332	-35,804	-35,868	-9,762	-42,545	-16,197	-31,187	-25,592	-6,062	-41,950	26,932	-29,651	-31,227	-24,699	-24,824	-16,301	0	0	0
Total Cashflows From Investing Activities	0	0	0	-35,722	-8,678	97,722	-2,522	-143,156	-19,905	-19,905	90,021	-26,394	-315,481	-8,500	-7,000	16,044	51,994	-15,937	-54,060	-74,167	-45,594	13,522	9,078	26,513	-25,880	-21,774	2,023	22,395	23,320	-15,095	-24,498	11,693	99,288	-47,875	34,045	73,710	-8,411	-56,649	-11,234	14,130	-1,426	-99,609	-73,533	-45,012	146	-33,712	-33,101	8,384	-55,819	-60,366	-50,469	0	0	0	0	0	1,736	21,205	0	2,532	0	0	0	0	110,592	69,501	27,756	20,358	0	0	0	0	3,339	4,204	16,810	9,270	0	0	0	0	51,576

Income Statement

Currency in USD. All numbers in thousands.

	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31	2005-12-31	2004-12-31	2003-12-31	2002-12-31	2001-12-31	2000-12-31
Cost Of Revenue	78,345	13,793	13,832	1,788	0	0	1,355	1,393	2,619	41,253	170,921	145,457	130,449	98,646	100,290	106,381	186,509	194,559	157,503	110,523	70,862	78,115	-	43,188
Depreciation And Amortization	35,705	5,581	13,832	13,840	13,874	13,872	13,982	13,954	13,933	12,175	8,203	7,326	7,583	6,336	5,541	6,962	4,058	4,198	4,107	4,812	5,209	5,124	9,568	8,992
Discontinued Operations	0	0	0	0	0	0	0	0	0	-94,934	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Ebit	113,885	209,991	426,206	303,164	217,850	222,937	177,744	97,998	19,110	-36,638	-161,353	-12,539	-109,322	-78,323	-79,071	-82,366	-168,565	-179,170	-149,556	-103,395	-72,466	-83,083	-63,341	-103,927
Ebitda	149,590	215,572	361,363	317,004	231,724	236,809	191,726	111,952	33,043	-24,463	-153,150	-5,213	-101,739	-71,987	-73,530	-75,404	-164,507	-174,972	-145,449	-98,583	-67,257	-77,959	-53,773	-94,935
Effect Of Accounting Charges	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Extraordinary Items	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Gross Profit	245,918	317,546	391,866	337	261,016	261,004	217,217	133,569	53,949	8,433	4,758	135,758	24,512	24,223	24,374	23,096	22,002	19,587	12,054	8,940	3,605	156	-	-43,188
Income Before Tax	194,098	286,949	445,276	354,245	232,895	210,255	134,272	59,536	-18,760	-73,530	-170,701	-18,542	-115,344	-83,862	-85,302	-98,623	-159,997	-166,044	-143,164	-102,654	0	0	-	-
Income Tax Expense	14,376	66,687	76,439	60,431	41,902	-196,073	4	49,452	50,340	134,535	1,838	5,543	415	83,862	85,302	439	-8,568	-13,126	-6,392	-741	-1,883	-3,856	-9,568	-8,992
Interest Expense	19,157	15,789	19,070	18,331	18,660	23,954	43,601	52,416	51,803	36,892	9,348	6,003	6,022	6,044	6,052	5,681	93	523	577	823	0	0	0	0
Interest Income	14,220	6,369	1,839	1,524	5,540	1,660	1,311	582	51,460	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Minority Interest	0	-6,341	102,983	69,412	33,705	11,272	129	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Net Income	179,722	213,921	265,854	224,402	157,288	395,056	134,143	59,536	-18,760	-168,464	-170,701	-18,542	-115,344	-83,862	-85,302	-93,643	-159,997	-166,044	-143,164	-102,654	-70,583	-79,227	-64,845	-94,935
Net Income Applicable To Common Shares	0	213,921	265,854	224,402	157,288	395,056	134,143	59,536	-18,760	-168,464	-170,701	-18,542	-115,344	0	0	0	0	0	0	0	0	0	-	-
Net Income From Continuing Ops	49,877	220,262	368,837	293,814	190,993	406,328	134,272	59,536	-18,760	-73,530	-170,701	-18,542	-115,344	0	0	0	0	0	0	0	0	0	-	-
Net Interest Income	-3,013	-9,420	-17,231	-16,807	-13,120	-22,294	-42,290	-51,834	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Non Operating Income Net Other	0	0	87,404	51,453	0	-4,042	-5,731	2,964	1,463	-2,709	7,510	460	415	0	0	0	0	0	0	0	0	0	-	-
Non Recurring	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Operating Income	113,885	209,991	375,103	321,123	246,360	238,251	183,604	108,988	31,580	-33,929	-168,863	-12,999	-109,737	-78,323	-81,361	-93,204	-168,565	-179,170	-149,556	-103,395	-72,466	-83,083	-74,413	-103,927
Other Items	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Other Operating Expenses	210,378	124,344	16,763	15,671	14,656	22,753	33,613	24,581	22,369	42,362	173,621	148,757	134,249	102,546	104,590	110,881	190,567	198,757	161,610	112,335	76,071	83,239	53,773	103,927
Preferred Stock And Other Adjustments	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Reconciled Depreciation	33,265	5,581	13,832	13,840	13,874	13,872	13,982	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Research Development	33,922	41,432	576	1,788	559	0	1,355	1,393	2,619	7,498	125,181	117,898	103,568	75,070	77,524	82,020	155,254	166,564	134,677	86,996	61,704	66,481	53,773	49,802
Selling And Marketing Expenses	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Selling General Administrative	89,367	63,538	16,187	13,883	14,656	22,753	32,258	23,188	19,750	34,864	48,440	30,859	30,681	27,476	27,066	28,861	35,313	32,193	26,933	28,339	0	0	-	-
Tax Provision	18,332	66,687	76,439	60,431	41,902	-196,073	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Total Operating Expenses	132,033	110,551	16,763	15,671	14,656	22,753	33,613	24,581	22,369	42,362	173,621	148,757	134,249	102,546	104,590	110,881	190,567	198,757	161,610	112,335	76,071	83,239	53,773	60,739
Total Other Income Expense Net	80,213	76,958	70,173	33,122	-13,465	-27,996	-49,332	2,382	1,120	-3,272	6,732	-5,543	-5,607	-5,539	-1,145	-5,419	8,568	13,126	6,392	3,741	0	0	-	-
Total Revenue	324,263	331,339	391,866	336,794	261,016	261,004	217,217	133,569	53,949	8,433	4,758	135,758	24,512	24,223	24,374	23,096	22,002	19,587	12,054	8,940	3,605	156	-	-

	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30	2004-06-30	2004-03-31	2003-12-31	2003-09-30	2003-06-30	2002-12-31
Cost Of Revenue	23,124	10,182	8,979	10,349	10,113	3,680	3,591	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1,489	4,411	5,811	5,992	6,093	6,386	6,872	5,910	5,356	6,568	6,616	5,488	5,100	5,547	6,124	188	10,541	10,728	188	8,890	8,122	8,220	8,095	33,914	32,891	35,477	39,149	38,813	33,581	28,289	25,983	23,236	23,587	24,075	25,312	23,048	25,105	25,492	25,404	19,897	24,981	24,934	34,107	38,113	39,422	52,189	56,785	44,651	46,108	48,716	55,084	46,275	41,348	35,133	34,747	32,336	24,763	32,073	21,351	21,301	17,111	32,450	78,115
Depreciation And Amortization	9,994	9,994	8,433	3,805	4,070	5,415	3,591	3,501	3,456	3,458	3,458	3,460	3,458	3,461	3,458	3,463	3,474	3,320	3,541	3,539	3,468	3,468	3,468	3,468	3,495	3,496	3,495	3,496	3,496	3,491	3,484	3,483	3,484	3,483	3,483	3,483	3,455	2,530	2,790	3,400	2,519	1,794	1,992	1,898	1,864	1,890	1,662	1,910	2,124	2,052	1,757	1,650	1,639	1,560	1,622	1,515	1,515	1,497	1,324	1,205	1,218	1,588	2,318	1,838	1,533	834	820	871	1,110	1,047	1,061	980	1,015	1,035	971	1,086	1,186	1,195	548	-	0	-	-	0
Discontinued Operations	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-51,521	0	-43,413	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Ebit	37,525	21,008	30,181	47,731	24,747	24,694	3,718	25,643	51,648	97,759	119,026	118,553	74,296	41,687	101,296	85,885	63,041	55,060	52,834	46,915	72,268	52,327	61,104	37,238	66,739	33,021	48,162	30,367	34,974	24,645	24,269	14,109	13,864	4,996	1,694	-1,444	-3,360	-9,194	-9,546	-66,059	-48,243	-45,083	-33,405	-33,387	-29,824	-33,192	-37,371	84,130	-35,504	-29,121	-23,539	-21,157	-17,933	-19,845	-19,432	-21,113	-20,903	-21,093	-21,293	-15,782	-14,862	-20,520	-16,684	-30,300	-33,846	-34,757	-47,704	-52,258	-41,224	-41,447	-44,813	-51,686	-43,912	-39,377	-33,191	-33,076	-27,782	-23,321	-26,694	0	0	0	0	0
Ebitda	47,519	31,002	38,614	51,536	28,817	30,109	7,309	29,144	26,025	101,217	122,484	122,013	77,754	45,148	104,754	89,348	66,515	58,380	56,375	50,454	75,736	55,795	64,572	40,706	70,234	36,517	51,657	33,863	38,470	28,136	27,753	17,592	17,348	8,479	5,177	2,039	95	-6,664	-6,756	-62,659	-45,724	-43,289	-31,413	-31,489	-27,960	-31,302	-35,709	86,040	-33,380	-27,069	-21,782	-19,507	-16,294	-18,285	-17,810	-19,598	-19,388	-19,596	-19,969	-14,577	-13,644	-18,932	-14,366	-28,462	-32,313	-33,923	-46,884	-51,387	-40,114	-40,400	-43,752	-50,706	-42,897	-38,342	-32,220	-31,990	-26,596	-22,126	-26,146	-	0	-	-	0
Effect Of Accounting Charges	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Extraordinary Items	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Gross Profit	66,148	57,077	72,013	66,023	55,690	63,577	108,220	90,059	107,680	97,862	100,806	85,518	90,476	88,694	78,946	78,678	75,971	65,755	64,107	55,183	79,858	61,680	67,086	52,380	69,520	48,643	58,562	40,492	43,612	33,309	32,472	24,176	22,836	13,562	10,655	6,896	7,092	999	934	-23	1,648	439	1,327	1,344	5,798	1,430	1,430	127,099	5,362	6,431	6,389	6,331	6,942	5,302	6,264	5,714	3,822	5,515	5,493	9,544	5,947	5,999	5,505	5,645	5,630	5,669	5,305	5,398	4,930	5,524	4,837	4,296	3,378	3,006	2,913	2,757	2,740	2,637	1,782	0	0	0	0	0
Income Before Tax	61,201	85,952	5,805	41,140	-64,688	286,424	20,495	44,718	56,489	123,177	136,179	129,431	90,758	50,487	118,116	94,884	70,265	57,609	56,494	48,527	73,142	50,167	56,616	30,330	58,514	23,767	35,146	16,845	25,470	15,033	14,597	4,435	4,301	-4,584	-7,810	-10,667	-15,926	-21,549	-19,873	-67,703	-49,929	-46,985	-36,429	-37,360	-31,324	-34,692	-37,120	84,594	-37,007	-30,626	-25,045	-22,667	-83,862	-21,222	-20,806	-22,536	-85,302	-22,183	-21,692	-19,217	-15,780	-20,670	-31,873	-29,764	-159,997	-32,364	0	-49,450	-166,044	-37,780	-41,475	-48,952	-143,164	0	-31,716	-31,451	0	-22,287	0	0	0	0	0	0
Income Tax Expense	-330	3,906	4,525	6,275	3,626	57,077	-876	6,860	10,839	20,531	25,333	19,736	15,742	8,866	19,891	15,932	12,403	10,558	10,433	8,508	-196,073	10,572	8,049	11,114	8,024	16,255	12,684	12,498	12,190	12,885	11,280	13,097	12,992	13,018	12,918	12,706	12,566	-278	278	1,459	1,477	1,747	-5,357	3,973	1,344	158	-1,662	1,446	71	81	118	145	19,299	21,222	20,806	22,536	22,210	22,183	21,692	19,217	451	308	216	-536	-788	-2,393	-2,579	-2,808	-3,387	-3,667	-3,338	-2,734	-1,701	-1,591	-1,475	-1,625	1,389	-1,034	-548	0	0	0	0	0
Interest Expense	5,952	4,396	4,382	4,427	4,028	5,096	3,655	3,010	4,841	4,790	4,745	4,694	4,651	4,603	4,561	4,516	4,689	4,693	4,661	4,617	4,581	5,238	6,478	7,657	8,354	10,262	12,204	12,781	13,000	13,103	13,156	13,157	13,047	13,063	12,987	12,706	12,566	12,355	10,327	1,644	1,686	1,902	3,024	3,973	1,500	1,500	1,501	1,502	1,503	1,505	1,506	1,510	1,507	1,513	1,508	1,517	1,510	1,515	1,511	1,516	5,681	1,517	1,511	1,136	93	45	24	121	523	208	136	151	577	125	144	193	191	209	206	217	0	0	0	0
Interest Income	4,786	4,114	3,553	3,365	3,188	2,135	724	322	454	453	20	30	23	41	158	1,302	1,538	1,624	1,403	975	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	-	0
Minority Interest	0	0	0	0	0	-36,176	20,432	22,085	35,305	30,208	21,898	15,572	21,113	13,403	21,381	13,515	28,621	16,708	20,019	6,229	5,455	3,078	1,990	749	129	456	0	0	0	0	0	0	0	0	0	0	152	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Income	61,531	82,046	1,280	34,865	-68,314	265,523	939	15,773	10,345	72,438	88,948	94,123	53,903	28,218	76,844	65,437	45,949	39,809	37,740	33,790	263,760	47,089	54,626	29,581	58,385	23,767	35,146	16,845	25,470	15,033	14,597	4,435	4,301	-4,584	-7,810	-10,667	-15,926	-21,271	-63,564	-67,703	-49,929	-46,985	-36,429	-37,360	-31,324	-34,692	-37,120	84,594	-37,007	-30,626	-25,045	-22,667	-19,299	-21,222	-20,806	-22,536	-22,210	-22,183	-21,692	-19,217	-15,925	-20,928	-27,026	-29,764	-33,058	-32,364	-45,125	-49,450	-37,837	-37,780	-41,475	-48,952	-42,211	-37,786	-31,716	-31,451	-29,171	-22,287	-25,598	0	0	0	0	0
Net Income Applicable To Common Shares	0	0	0	34,865	-68,314	265,523	939	15,773	10,345	72,438	88,948	94,123	53,903	28,218	76,844	65,437	45,949	39,809	37,740	33,790	263,760	47,089	54,626	29,581	58,385	23,767	35,146	16,845	25,471	15,033	14,597	4,435	4,301	-4,584	-7,810	-10,667	-15,926	-21,271	-63,564	-67,703	-49,927	-46,985	-36,429	-37,360	-31,324	-34,692	-37,120	84,594	0	-30,626	-25,045	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Income From Continuing Ops	61,531	82,046	1,280	34,865	-68,314	229,347	21,371	37,858	45,650	102,646	110,846	109,695	75,016	41,621	98,225	78,952	57,862	47,051	46,061	40,019	269,215	50,167	56,616	30,330	58,514	23,767	35,146	16,845	25,471	15,033	14,597	4,435	4,301	-4,584	-7,810	-10,667	35,595	-21,271	-20,151	-67,703	-49,927	-46,985	-36,429	-37,360	-31,324	-34,692	-37,120	84,594	0	-30,626	-25,045	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Interest Income	-1,166	-282	-829	-1,062	-840	-2,961	-2,931	-2,688	-4,387	-4,337	-4,725	-4,664	-4,628	-4,562	-4,403	-3,214	-3,151	-3,069	-3,258	-3,642	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	-	0
Non Operating Income Net Other	0	0	0	17,836	0	0	-59,128	-30,323	-45,036	33,414	44,384	54,642	10,622	-29,340	46,886	23,285	0	0	0	976	503	-2,256	419	-2,708	459	-5,993	-480	283	810	218	1,876	60	55	45	69	1,294	-3,490	348	248	185	211	155	8,381	-1,237	156	158	90	56	0	81	118	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	-	0
Non Recurring	0	0	0	0	0	5,096	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Operating Income	37,525	90,348	10,187	47,731	24,747	24,694	82,554	77,729	104,527	94,553	96,540	79,483	84,787	84,430	75,791	76,115	73,639	60,793	59,760	52,168	77,220	57,661	62,675	40,695	66,409	40,022	47,830	29,343	37,661	27,918	25,877	17,532	17,293	8,434	5,108	745	130	-9,542	-9,794	-66,244	-48,452	-45,238	-41,786	-33,387	-29,980	-33,350	-35,709	86,040	-35,575	-29,202	-23,657	-21,302	-17,933	-19,845	-19,432	-21,113	-20,579	-21,081	-21,353	-18,348	-15,474	-20,620	-26,810	-30,300	-33,846	-34,757	-47,704	-52,258	-41,224	-41,447	-44,813	-51,686	-43,912	-39,377	-33,191	-33,076	-27,782	-23,321	-26,146	0	0	0	0	0
Other Items	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Operating Expenses	51,747	49,318	52,468	46,477	41,622	44,726	25,666	12,330	3,153	3,309	4,266	6,035	5,689	4,264	3,155	2,563	2,332	4,962	4,347	3,015	2,638	4,019	4,411	11,685	3,111	6,133	6,425	6,912	5,951	5,391	6,595	6,644	5,543	5,128	5,547	6,151	7,150	10,541	10,728	66,409	50,100	45,677	43,113	34,731	35,778	34,780	37,139	41,059	40,937	35,633	30,046	27,633	24,875	25,147	25,696	26,827	24,563	26,602	26,816	26,609	21,115	26,569	27,252	35,945	39,476	40,426	53,009	57,656	46,154	46,971	49,650	55,982	47,290	42,383	36,104	35,833	30,522	25,958	27,928	0	0	0	0	0
Preferred Stock And Other Adjustments	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	-	0
Reconciled Depreciation	-3,927	9,994	8,433	3,805	4,070	5,415	3,591	3,501	3,456	3,458	3,458	3,460	3,458	3,461	3,458	3,463	3,474	3,320	3,541	3,539	3,468	3,468	3,468	3,468	3,495	3,496	3,495	3,496	3,496	3,491	3,484	3,483	3,484	3,483	3,483	3,483	3,455	2,530	2,790	3,400	2,519	1,794	1,992	1,898	1,864	1,890	1,662	1,910	2,124	2,052	1,757	1,650	1,639	1,560	1,622	1,515	1,515	1,497	1,324	1,205	1,218	1,588	2,318	1,838	1,533	834	820	871	1,110	1,047	1,061	980	1,015	1,035	971	1,086	1,186	1,195	0	-	0	-	-	0
Research Development	2,356	3,989	14,989	12,588	10,049	11,725	13,884	5,838	40	449	38	49	219	1,010	559	0	0	0	0	0	0	0	0	0	342	311	348	354	345	286	370	392	722	547	638	712	777	1,909	2,125	43,387	33,631	33,395	31,739	26,416	28,120	27,026	26,008	33,202	32,469	27,837	22,798	20,464	17,476	18,537	18,705	20,351	18,406	19,541	20,020	19,557	15,170	20,075	19,996	26,779	30,935	31,964	43,497	48,858	38,002	39,103	40,751	48,708	41,023	36,249	28,050	29,355	27,302	20,411	19,642	19,166	35,017	27,987	27,987	69,879
Selling And Marketing Expenses	0	0	0	0	884	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3,000	2,292	0	-	0	-	-	0
Selling General Administrative	26,319	28,636	23,542	19,735	18,274	238,914	11,782	6,492	3,113	2,860	4,228	5,986	5,470	3,254	2,596	2,563	2,332	4,962	4,347	3,015	2,638	4,019	4,411	11,685	2,769	5,822	6,077	6,558	5,606	5,105	6,225	6,252	4,821	4,581	4,909	5,439	6,373	8,632	8,603	22,834	16,469	12,282	11,374	8,315	7,658	7,754	11,131	7,857	8,468	7,796	7,248	7,169	7,399	6,610	6,991	6,476	6,157	7,061	6,796	7,052	5,945	6,494	7,256	9,166	8,541	8,462	9,512	8,798	8,152	7,868	8,899	7,274	6,267	6,134	8,054	6,478	6,220	3,255	0	0	0	0	0	0
Tax Provision	-330	3,906	4,525	6,275	3,626	57,077	-876	6,860	10,839	20,531	25,333	19,736	15,742	8,866	19,891	15,932	12,403	10,558	10,433	8,508	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	-	0
Total Operating Expenses	28,623	39,136	43,489	36,128	31,509	41,046	25,666	12,330	3,153	3,309	4,266	6,035	5,689	4,264	3,155	2,563	2,332	4,962	4,347	3,015	2,638	4,019	4,411	11,685	3,111	6,133	6,425	6,912	5,951	5,391	6,595	6,644	5,543	5,128	5,547	6,151	7,150	10,541	10,728	66,221	50,100	45,677	43,113	34,731	35,778	34,780	37,139	41,059	40,937	35,633	30,046	27,633	24,875	25,147	25,696	26,827	24,563	26,602	26,816	26,609	21,115	26,569	27,252	35,945	39,476	40,426	53,009	57,656	46,154	46,971	49,650	55,982	47,290	42,383	36,104	35,833	30,522	25,958	27,928	0	0	0	0	0
Total Other Income Expense Net	23,676	68,293	-21,890	-6,591	-89,435	261,730	-62,059	-33,011	-48,038	28,624	39,639	49,948	5,971	-33,943	42,325	18,769	-3,374	-3,184	-3,266	-3,641	-4,078	-7,494	-6,059	-10,365	-7,895	-8,857	-5,093	-4,190	638	56	1,719	-32	3	-45	-16	1,178	-3,607	255	83	-3	-2	-37	8,192	-3,973	-1,344	-1,342	-1,411	-1,446	-1,432	-1,424	-1,388	-1,365	-5,539	-1,377	-1,374	-1,423	162	6	-30	-1,283	-306	-50	-5,063	536	-126,151	2,393	0	2,808	-124,820	3,667	3,338	2,734	-99,252	0	1,475	1,625	0	1,034	0	0	0	0	0	0
Total Revenue	89,272	67,259	80,992	76,372	65,803	67,257	108,220	90,059	107,680	97,862	100,806	85,518	90,476	88,694	78,946	78,678	75,971	65,755	64,107	55,183	79,858	61,680	67,086	52,380	69,520	48,643	58,562	40,492	43,612	33,309	32,472	24,176	22,836	13,562	10,655	6,896	7,280	999	934	165	1,648	439	1,327	1,344	5,798	1,430	1,430	127,099	5,362	6,431	6,389	6,331	6,942	5,302	6,264	5,714	3,822	5,515	5,493	9,544	5,947	5,999	5,505	5,645	5,630	5,669	5,305	5,398	4,930	5,524	4,837	4,296	3,378	3,006	2,913	2,757	2,740	2,637	1,782	1,387	1,276	997	1,332	156

Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue	324,263
Cost of Revenue	-78,345
Gross Profit	245,918	245,918

Operating Income (+$)
Gross Profit	245,918
Operating Expense	-132,033
Operating Income	113,885	113,885

Operating Expense (+$)
Research Development	33,922
Selling General Administrative	89,367
Selling And Marketing Expenses	0
Operating Expense	132,033	123,289

Net Interest Income (+$)
Interest Income	14,220
Interest Expense	-19,157
Other Finance Cost	-1,924
Net Interest Income	-3,013

Pretax Income (+$)
Operating Income	113,885
Net Interest Income	-3,013
Other Non-Operating Income Expenses	0
Income Before Tax (EBT)	194,098	33,672 EBIT - interestExpense = 94,728 194,098 198,879
Interest Expense	19,157
Earnings Before Interest and Taxes (EBIT)	113,885	213,255
Earnings Before Interest and Taxes (EBITDA)	149,590

After tax Income (+$)
Income Before Tax	194,098
Tax Provision	-18,332
Net Income From Continuing Ops	49,877	175,766
Net Income	179,722
Net Income Applicable To Common Shares	0

Non-recurring Events
Discontinued Operations	0
Extraordinary Items	0
Effect of Accounting Charges	0
Other Items	0
Non Recurring	0
Other Operating Expenses	210,378
Total Other Income/Expenses Net	80,213	3,013

Technical Analysis of Innoviva Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Innoviva Inc. The general trend of Innoviva Inc is BULLISH with 28.6% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Innoviva Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitions	Bullish trend (28.6%)		Bearish trend (-28.6%)
Overbought to neutral	Bullish pullback	=	Bearish reversal
Upper to lower neutral	Bullish correction	=	Bearish continuation
Nuetral to oversold	Oversold	=	Oversold
Oversold to neutral	Bullish reversal	=	Bearish correction
Lower to upper neutral	Bullish continuation	=	Bearish pullback
Nuetral to overbought	Overbought	=	Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.

Score

Let's take a look at the Support & Resistance of Innoviva Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 15.36 < 15.36 < 15.39.

The bearish price targets are: 14.33 > 14.33 > 14.08.

Tweet this

Innoviva Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

Moving averages are lagging trend indicators.
There are many types of moving averages.
Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Innoviva Inc. The current mas is .

The long score for the Moving Averages is 9/14.
The longshort score for the Moving Averages is 4/(-14 +14).

MA 20 trending up: The MA 20 is trending up. +1
Close > MA 20: The price is above the MA 20. +1
MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
MA 50 trending down: The MA 50 is trending down. -1
Close > MA 50: The price is above the MA 50. +1
MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
MA 100 trending up: The MA 100 is trending up. +1
Close < MA 100: The price is below the MA 100. -1
MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
MA 200 trending up: The MA 200 is trending up. +1
Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving Average	Amount of candles	vs. MA 50	vs. MA 100	vs. MA 200
MA 20	20
MA 50	50	-
MA 100	100	-	-
MA 200	200	-	-	-

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Shows the moving average of the selected period.

There are four types of indicators:

Trend indicators
Momentum indicators
Volatility indicators
Volume indicators

There are various kinds of moving averages:

Simple moving average (SMA);
Exponential moving average (EMA);
Smoothed moving average (SMMA);
Linear weighted moving average (LWMA).

The moving average looks at a certain period of time and it calculates the price average. The various types of averages are using various formulas. Don’t worry, you don’t have to memorize any formula. All moving averages are calculated automatically by basically every charting software you use. But it’s good to know how moving averages are actually calculated.

Simple moving average

SMA is calculated by summing up the price closures of the selected period. The price is then divided by the selected period. For example, when using the 21 day moving average you sum up all the closing prices for each day and divide that by 21. The result is a line on the chart representing the average. Because it’s an average in the selected timeframe, the trend is always lagging. An moving average looks like this on the chart:

Source: Tradingview.com

In this case, the blue line represents a 21 day moving average. Because the average is based on results from the past, the indicator will always lag behind. For example, when price would suddenly go up, the moving average won't immediately follow.

All other moving averages discussed below look the same on the chart. The only difference is that the line will move in different directions based on the maths behind the used indicators and the amount of days used to determine the average.

Exponential moving average

The EMA gives more weight to the latest closing prices by giving them more value in the equation. EMA is calculated by adding a certain percentage to the latest closing prices:

EMA = (CLOSE (i) * P) + (EMA (i - 1) * (1 - P))

Where:

CLOSE (i) = current period close price.
EMA (i - 1) = value of the Moving Average of a preceding period.
P = the percentage of using the price value.

Smoothed moving average

A smoothed moving average is an exponential moving average with a long lookback period. Older prices are reduced in weight but are never left out in the calculation. Unlike SMA and EMA where prices are removed when they are beyond the selected period. SMMA is a combination of the SMA and EMA. The main advantage is that it smooths out fluctuations in price.

Linear weighted moving average

The LWMA gives the latest price the highest weight and then lineary scales down with each price before that. The result is that the LWMA reacts quicker to changes in price than the SMA or EMA. The formula:

LWMA = ((Pn∗W1)+(Pn−1∗W2)+(Pn−2∗W3)...) / ∑W

Where:

P = Price for the period.
n = The most recent period, n-1 is the prior period, and n-2 is two periods prior.
W = The assigned weight to each period, with the highest weight going first and then descending linearly based on the number of periods being used.

Moving averages are widely used by many traders. Which moving average you need depends on your trading strategy. Common practise is using a combination of multiple periods. For example, the EMA21, EMA50, EMA100 and EMA200. How does that look on a chart:

Source: Tradingview.com

The lowest (purple) line on the chart represents the EMA200 then following up the EMA100, EMA50 and EMA21.

You can use moving averages to determine a trend. The 200 moving average is mostly used as a baseline for determining the current trend:

When the 200 moving average is moving up it is considered a bullish trend.
When the 200 moving average is down it is considered a bearish trend.
When moving averages are flatlined, there is no clear trend so you should look for market structure, consolidation or trend reversals. Depending on how you want to trade.

This is not set in stone. Most trading strategies use multiple moving averages each with different settings. While one strategy might use the EMA20, the other uses the SMA21. There can be hundreds of different variations. Moving averages can also be used as support and resistance. More often than not, prices will bounce on moving averages.

Innoviva Inc Daily Moving Averages Chart

2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

MACD is a lagging momentum indicator.
Uses two moving averages.
Can show buy or sell signals based on momentum.
Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Innoviva Inc. The current macd is -0.05420499.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Innoviva Inc price going up in the near term. +2
MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Innoviva Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Innoviva Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1

Innoviva Inc Daily Moving Average Convergence/Divergence (MACD) Chart

2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.

Score

Let's take a look at the Directional Movement Index (DMI) of Innoviva Inc. The current adx is 14.42.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Innoviva Inc shares, leading to potential upward momentum in its price. +1
PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1

Innoviva Inc Daily Directional Movement Index (DMI) Chart

2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

Parabolic SAR (stop and reverse) is a lagging trend indicator.
Shows the current trend.
Shows potential entry signals.
Shows potential exit signals.
Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Innoviva Inc. The current sar is 14.34.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

Leading momentum indicator, meaning the signals are instant.
Ranges between 0 and 100.
Above 70 is considered overbought.
Below 30 is considered oversold.
Above or below 50 can also be used to determine price trend or support and resistance.
RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Innoviva Inc. The current rsi is 59.23. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
Trending up: The RSI is trending up. +1

Measures the speed and change of price movements.

There are four types of indicators:

Trend indicators
Momentum indicators
Volatility indicators
Volume indicators

The RSI measures the magnitude of recent price changes to determine if the asset is overbought or oversold.

Overbought (RSI above 70) means that the trading price is above its intrinsic value. This might indicate a sell or short signal.
Oversold (RSI below 30) means that the trading price is below its intrinsic value. This might indicate a buy or long signal.
RSI levels above or below 50 can also be used to determine a trend.
RSI divergence looks at a deviation between RSI and price movement.
Can be used in many different ways.

Original usage

Keep in mind that almost every indicator can be used in different ways. Even beyond the orginal settings. The relative strength index was developed by J. Welles Wilder. Wilder recommended a smoothing period of 14 days. That means a 14 day moving average (read more about this setting below). Another quote from the wikipedia page:

Wilders also considers the RSI 50 line as both support and resistance. I recommend to always read the original settings first before using an indicator. Many traders and websites are using their own version of the indicator which might be confusing.

How you can use RSI (Divergence)

First and foremost, there is no real right or wrong usage of the RSI indicator. You can use it in any way you want. Wilder recommends using a 14 day average but you can make it 50 or 100 if you like. Just keep in mind that using an indicator is just part of a larger trading plan. In other words, it’s not recommended to do any trading or investing based on a single indicator like the RSI.

The RSI is measured on a scale between 0 and 100. From 30 till 0 is considered oversold. and from 70 -100 is overbought. The RSI is a leading indicator, meaning the signals are instant.

I like to use the RSI as a trend\momentum indicator and not as an overbought or oversold indicator. I use the middle (50) as the baseline. When prices go above RSI 50 the trend is bullish and can indicate long positions. When below 50 it is considered bearish and can indicate short positions. Other traders use the 70 and 30 levels as overbought/oversold depending on the used strategy. The RSI indicator looks like this:

Source: Tradingview.com

The general concensus is that an RSI above 70 indicates that the security is overbought. In other words, the price this security is trading for is to high and should come down. So if RSI hits 70 or above this might indicate a sell signal or taking a short position (expecting the price will go down). Although RSI above 70 indicates the security is trading above it's fair value, that does not mean the price will go down.

Use tradingview to add indicators

I highly recommend using tradingview to add indicators to a chart. It has all the indicators you can think off and can add them for free (up to three indicators) to any chart you want. You can see that the levels 30 and 70 are marked with a dotted line. If you want you can remove these lines or give it another colour using Tradingview. You can also adjust the moving average used. You can also find RSI indicators made by the community that include other settings like RSI divergences.

Tradingview

Use Tradingview to (back)test your strategies and add hundreds of indicators created by the community.

View tool on Tradingview.com

RSI divergence

RSI is not only used to determine momentum but can also spot reversals or continuations of the trend. A reversal means that the trend is going in the opposite direction. From bullish to bearish or from bearish to bullish. These reversals can be spotted by looking at the price and the direction of the RSI. When the price is going up but the RSI is going down that means there is a divergence. This is also the case when RSI goes up but price is going down.

There are four types of divergences:

Regular bullish divergence
Regular bearish divergence
Hidden bullish divergence
Hidden bearish divergence

Regular bullish divergence

With a regular bullish divergence, the price is making lower highs but the oscillator (in this case the RSI) is making higher lows. A regular bullish divergence might indicate the end of the current trend. You’ll see regular bullish divergences mostly at the end of a downtrend. But that does not mean that every regular bullish divergence is a trend reversal.

Price is making lower highs
RSI is making higher lows
Indicating bullish reversal (price might go up)

Source: Tradingview.com

Regular bearish divergence

With a regular bearish divergence the price is making higher highs but the oscillator (in this case the RSI) is making lower highs. This might indicate the end of an uptrend.

Price is making higher highs
RSI is making lower highs
Indicating bearish reversal

Source: Tradingview.com

Hidden bullish divergence

With a hidden bullish divergence, the price is making a higher low while the RSI is making a lower low. This might indicate bullish trend continuation.

Price is making higher lows
RSI is making lower lows
Indicating bullish continuation

Source: Tradingview.com

As you have noticed, you can have multiple divergences in a row.

Hidden bearish divergence

With a hidden bearish divergence, price is making lower highs but RSI is making higher highs. This might indicate bearish trend continuation.

Price is making lower highs
RSI making higher highs
Indicating bearish continuation

Source: Tradingview.com

You can find many cheatsheets of RSI divergences online. Search for "RSI divergence overview" and you'll find a lot of examples. You can print these to learn the various types of divergences.

Innoviva Inc Daily Relative Strength Index (RSI) Chart

3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

Leading momentum indicator, meaning the signals are instant.
Used to determine overbought and oversold areas much like the RSI.
Ranges between 0 and 100.
Above 80 is considered overbought.
Below 20 is considered oversold.
Consists of two lines named K and D.
K compares the highest high and lowest low on the selected price range.
The D line is a moving average of the K line.
Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Innoviva Inc. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
STOCH > 80: The STOCH %K is above 80 and overbought. +2
STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Innoviva Inc price going up in the near term. +2
Trending up: The STOCH %K is trending up. +1

Innoviva Inc Daily Stochastic Oscillator Chart

3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

Lagging or leading Momentum indicator
When the CCI is above zero, the price is above the historical average
When the CCI is below zero, the price is below the historical average
Used for spotting trends
- If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
- If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Innoviva Inc. The current cci is 99.11.

Innoviva Inc Daily Commodity Channel Index (CCI) Chart

3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

Lagging momentum indicator
Ranges between +100 and -100
Considered overbought above +50
Considered oversold below -50
It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Innoviva Inc. The current cmo is 35.00.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1

Innoviva Inc Daily Chande Momentum Oscillator (CMO) Chart

3.5 Williams %R

Shows the current price relative to the highest high over the last 14 days.

Lagging momentum indicator
Ranging between 0 and -100
Above -20 is considered overbought
Below -80 is considered oversold
Is prone to give false signals

Score

Let's take a look at the Williams %R of Innoviva Inc. The current willr is -17.15686275.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

Lagging volatility indicator
Uses 3 bands: one upper, one lower and one in the middle
Works best when the middle band reflects an intermediate trend (MA20).
When the price is moving closer to the upper band, the market might be overbought
When the price is moving closer to the lower band, the market might be oversold

Score

Let's take a look at the Bollinger Bands of Innoviva Inc.

Innoviva Inc Daily Bollinger Bands Chart

4.2 Average True Range (ATR)

Measures market volatility

Leading volatility indicator
Can be used to determine stop-loss positions
Calculated by:
- Current high minus the current low
- Current high minus the previous close
- Current low minus the previous close
The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Innoviva Inc. The current atr is 0.31655509.

Innoviva Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Measures market volatility

Leading momentum indicator
Calculation:
- If the closing price is above the previous closing price: OBV = previous OBV + current volume
- If the closing price is below the previous closing price: OBV = previous OBV - current volume
- If the closing price is the same as the previous closing price than the OBV is the same.
Can be used to confirm price trends
Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Innoviva Inc. The current obv is -6,855,878.

Innoviva Inc Daily On-Balance Volume (OBV) Chart

5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

Lagging momentum indicator
Looks like RSI but uses volume as an extra metric (RSI only considers price)
Above 80 is considered overbought
Below 20 is considered oversold
Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Innoviva Inc. The current mfi is 65.81.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

MFI > 50: +1

Innoviva Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

Type	Notification	Date
Currently no notifications for Innoviva Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

Date	Indicator	Signal
2023-12-01	MACD	LONG ENTRY	SHORT CLOSE	The MACD line crosses above the signal line.
	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
2023-12-04	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2023-12-06	RSI	SHORT ENTRY	LONG CLOSE	70 crossover to downside
	STOCH	LONG EXIT		The %K line crosses below the %D line.
2023-12-07	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
2023-12-08	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2023-12-11	MFI	LONG ENTRY	SHORT CLOSE	80 crossover to upside
2023-12-12	STOCH	LONG EXIT		The %K line crosses below the %D line.
2023-12-14	RSI	SHORT ENTRY	LONG CLOSE	70 crossover to downside
	MFI	SHORT ENTRY	LONG CLOSE	80 crossover to downside
2023-12-15	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
	MFI	LONG ENTRY	SHORT CLOSE	80 crossover to upside
2023-12-18	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2023-12-20	STOCH	LONG EXIT		The %K line crosses below the %D line.
2023-12-21	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2023-12-22	STOCH	LONG EXIT		The %K line crosses below the %D line.
2023-12-27	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2023-12-28	STOCH	LONG EXIT		The %K line crosses below the %D line.
2023-12-29	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
2024-01-02	MACD	SHORT ENTRY	LONG CLOSE	The MACD line crosses below the signal line.
	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
2024-01-04	MACD	LONG ENTRY	SHORT CLOSE	The MACD line crosses above the signal line.
	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
2024-01-05	MACD	SHORT ENTRY	LONG CLOSE	The MACD line crosses below the signal line.
	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-01-08	RSI	SHORT ENTRY	LONG CLOSE	70 crossover to downside
	MFI	SHORT ENTRY	LONG CLOSE	80 crossover to downside
2024-01-10	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
2024-01-11	DMI	SHORT ENTRY	LONG CLOSE	The +DI crossed the -DI to the downside. The trend is reversing to a down trend.
	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
	RSI	SHORT ENTRY	LONG CLOSE	70 crossover to downside
	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-01-16	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-01-17	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
2024-01-19	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
2024-01-22	DMI	LONG ENTRY	SHORT CLOSE	The +DI crossed the -DI to the upside. The trend is reversing to an up trend.
	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2024-01-24	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-01-25	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-01-29	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
2024-01-30	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-01-31	DMI	SHORT ENTRY	LONG CLOSE	The +DI crossed the -DI to the downside. The trend is reversing to a down trend.
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
2024-02-02	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
	BB	LONG ENTRY	SHORT CLOSE	Price closed below the lower band.
	ATR	SHORT ENTRY	LONG CLOSE	Price closed below (close - ATR).
2024-02-05	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
2024-02-06	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-02-07	STOCH	LONG EXIT		The %K line crosses below the %D line.
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
	BB	LONG ENTRY	SHORT CLOSE	Price closed below the lower band.
2024-02-08	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-02-13	STOCH	LONG EXIT		The %K line crosses below the %D line.
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-02-14	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-02-15	DMI	LONG ENTRY	SHORT CLOSE	The +DI crossed the -DI to the upside. The trend is reversing to an up trend.
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
2024-02-16	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
2024-02-20	DMI	SHORT ENTRY	LONG CLOSE	The +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-02-22	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-02-26	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-02-27	STOCH	LONG EXIT		The %K line crosses below the %D line.
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-02-28	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
2024-02-29	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-03-01	DMI	LONG ENTRY	SHORT CLOSE	The +DI crossed the -DI to the upside. The trend is reversing to an up trend.
	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-03-04	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
2024-03-05	STOCH	LONG EXIT		The %K line crosses below the %D line.
	BB	LONG ENTRY	SHORT CLOSE	Price closed below the lower band.
2024-03-06	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-03-07	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-03-08	DMI	SHORT ENTRY	LONG CLOSE	The +DI crossed the -DI to the downside. The trend is reversing to a down trend.
	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-03-12	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-03-13	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-03-15	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-03-18	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
2024-03-20	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-03-21	MACD	LONG ENTRY	SHORT CLOSE	The MACD line crosses above the signal line.
	DMI	LONG ENTRY	SHORT CLOSE	The +DI crossed the -DI to the upside. The trend is reversing to an up trend.
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
2024-03-25	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
2024-03-26	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
2024-03-27	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
2024-04-01	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-04-02	DMI	SHORT ENTRY	LONG CLOSE	The +DI crossed the -DI to the downside. The trend is reversing to a down trend.
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
	ATR	SHORT ENTRY	LONG CLOSE	Price closed below (close - ATR).
2024-04-03	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
2024-04-08	MACD	SHORT ENTRY	LONG CLOSE	The MACD line crosses below the signal line.
	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-04-10	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-04-11	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-04-12	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-04-15	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-04-17	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-04-19	MACD	LONG ENTRY	SHORT CLOSE	The MACD line crosses above the signal line.
	DMI	LONG ENTRY	SHORT CLOSE	The +DI crossed the -DI to the upside. The trend is reversing to an up trend.
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
2024-04-22	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
2024-04-23	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside

6.3. Candlestick Patterns

Date	Candlestick Pattern

6.4. Technical Score

Let's check the technical score of Innoviva Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

Indicator	Condition		Value
Rsi	Greater than	50	59.226
Ma 20	Greater than	Ma 50	14.807
Ma 50	Greater than	Ma 100	15.050
Ma 100	Greater than	Ma 200	15.460
Open	Greater than	Close	14.950
Total			2/5 (40.0%)

Create your own Symbol Scanner

Get notifications about Innoviva Inc

I send you an email if I find something interesting about Innoviva Inc.

Innoviva Inc Buy, Hold or Sell?

Let's analyse Innoviva Inc together

Get notifications about Innoviva Inc

Quick analysis of Innoviva Inc (30 sec.)

What can you expect buying and holding a share of Innoviva Inc? (30 sec.)

How much money do you get?

What is your share worth?

+ What do you gain per year?

For what price can you sell your share?

1. Valuation of Innoviva Inc (5 min.)

$15.17

$7.94

$-6.23 - $41.66

$1.71 - $49.60

2. Growth of Innoviva Inc (5 min.)

Is Innoviva Inc growing?

How much money is Innoviva Inc making?

How much money comes from the company's main activities?

3. Financial Health of Innoviva Inc (5 min.)

4. Comparing to competitors in the Biotechnology industry (5 min.)

Industry Rankings (Biotechnology)

What can you expect buying and holding a share of Innoviva Inc? (5 min.)

What can you expect buying and holding a share of Innoviva Inc?

Speculation

Investing

How much money are you going to get?

When do you get the money?

How sure are you?

Linear %

Fundamentals of Innoviva Inc

About Innoviva Inc

Financial Health

Valuation

1.1. Profitability of Innoviva Inc.

1.1. Profitability

1.1.1. Net Profit Margin

Trends

Compared to industry (Biotechnology)

1.1.2. Return on Assets

Trends

Compared to industry (Biotechnology)

1.1.3. Return on Equity

Trends

Compared to industry (Biotechnology)

1.2. Operating Efficiency of Innoviva Inc.

1.2. Operating Efficiency

1.2.1. Operating Margin

Trends

Compared to industry (Biotechnology)

1.2.2. Operating Ratio

Trends

Compared to industry (Biotechnology)

1.3. Liquidity of Innoviva Inc.

1.3. Liquidity

1.3.1. Current Ratio

Trends

Compared to industry (Biotechnology)

1.3.2. Quick Ratio

Trends

Compared to industry (Biotechnology)

1.4. Solvency of Innoviva Inc.

1.3. Liquidity

1.4.1. Debt to Asset Ratio

Trends

Compared to industry (Biotechnology)

1.4.2. Debt to Equity Ratio

Trends

Compared to industry (Biotechnology)

2. Market Valuation of Innoviva Inc

2.1. Earnings Per Share

2.1. Price to Earnings Ratio

Trends

Compared to industry (Biotechnology)

Innoviva Inc
Buy, Hold or Sell?